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1INTRODUCTION
NAFLD is considered  as commonest liver problem of the western
world where about 15-40% general population are affected. NAFLD
stands as second and fourth cause for liver transplantation in large
transplantation centres and in the United States, respectively.
Approximately 20-30%and3-10%of Western adults and children are
suffering from NAFLD and this value reaches up to 70-80% in the obese
population[1]. NAFLD  has attained epidemic proportions even in
countries  at  low  risk,  such  as  China  (15%)and   Japan  (14%).  This
alarming increase in NAFLD is because  NAFLD progresses  from liver
failure to cirrhosis to HCC. Many factors contribute to develop NAFLD
including diabetes mellitus (T2DM) which can increase its risk and
severity. Peripheral insulin resistance is a central mechanism for the
pathogenesis of both entities.
 10-75% of NAFLD patients have T2DM and 21-72% of diabetic
patients  are  found  to  have  NAFLD[2]. The mortality rate in diabetic
patients due to cirrhosis is above 2 times the general population and
patients with NAFLD and DM have poorer prognosis in terms of higher
rates of cirrhosis and mortality. NAFLD and T2DM are conditions highly
dependent on genetic background and dietary factors[3].
2NAFLD is a spectrum with, simple steatosis (which remains stable
over a period  of years without progression in most patients) to
steatohepatitis and  advanced ?brosis ( more risk for developing
decompensated liver disease with portal hypertension to HCC, or death
unless  transplantation is done).
Hence they need close follow-up and surveillance for esophageal
varices and HCC and if required treatment.
Liver biopsy is gold standard to identify  steatohepatitis and
?brosis in NAFLD patients, but has several limitations such as cost,
sampling error, procedure-related morbidity and even mortality. Liver
enzymes and imaging (ultrasound or CT or MRI) will not exactly assess
steatohepatitis and ?brosis in these patients. Much interest developed for
non-invasive analysis using clinical prediction tools and biomarkers to
identify steatohepatitis and significant fibrosis.[4]
NAFLD Fibrosis Score (NFS) , BARD, AST to Platelet Ratio
Index (APRI), and FIB-4 are  the more widely investigated noninvasive
tools to cross-sectionally predict advanced fibrosis in NAFLD[5]. NAFLD
Fibrosis Score  consists of six variables (BMI, Age, hyperglycaemia,
platelet count, AST/ALT ratio , Albumin) and very useful clinical tool for
3detecting advanced ?brosis (bridging ?brosis and/or cirrhosis) with
higher likelihood in NAFLD patients.[6]
AUROC for NAFLD Score is 0.85 in predicting advanced fibrosis.
The Score of<1.455 had sensitivity of90% and speci?city of 60% to
exclude advanced ?brosis and the score of> 0.676 had sensitivity of 67%
and speci?city  of 97% to detect advanced ?brosis.[4]
An algorithmic approach in NAFLD was Proposed  in an
international study recently. According to that study, patients with a
lower NAFLD score below the cut-off level found to have a low risk for
signi?cant ?brosis and disease progression and they can be managed
safely in a primary care.
If the score is in the indeterminate or high range referral to  a
specialist care  is indicated. These patients are investigated further by non
invasive modalities such as specialised scan ssuch as Fibroscan
(Transient Elastography) /ARFI (Aquostic Radiation Force Impulse
imaging) or  with serum markers for steatohepatitis. Liver biopsy should
only be done for those patients where  non-invasive tests are
inconclusive. The serum marker panels can replace Fibroscan in this
algorithm later.[6]
4AIMS AND OBJECTIVES
1. To study the prevalence of Non-alcoholic fatty liver disease based
on ultrasound and study its clinical profile in type 2 diabetic
patients attending outpatient clinic and inpatients in the Stanley
medical college Hospital.
2.  To apply the simple non invasive scoring system (NAFLD
FIBROSIS SCORE) which helps in separating NAFLD patients
with and without advanced liver ?brosis by using clinical and
biochemical variables.
3.  To correlate the NAFLD Fibrosis score (Indeterminate and high
risk) in patients with high grade fatty liver (ultrasound) with the
liver stiffness measured by transient elastography (FIBROSCAN) .
5REVIEW OF LITERATURE
HISTORIC PERSPECTIVE:
The liver and fat storage, derived from the Latin term for liver,
ficatu, and the corresponding greek term, sycoti- common name for
fattened animal livers, iecaur ficatum and hepar sykoton. [9]
Macrovesicular steatosis with  inflammation and fibrosis in the liver of
obese subjects was known several decades ago [10] . Ludwig et alin
1980,coined a term NASH in non-alcoholics on the similar histological
findings in alcoholics. [11]
The research into etiopathogenesis, natural history, diagnosis and
treatment of NAFLD/NASH started in a Chronological order as
follows[12]
6INCIDENCE AND PREVALENCE:
In general population,10-24 % NAFLD was detected in various
countries. The estimation increases from 57.5 %[13] to 74 % [14,15] among
obese persons. NAFLD is responsible for abnormal, asymptomatic
elevation in liver function tests among the blood donors and in 90% cases
when no other liver etiology was found.[16] NAFLD prevalence  increased
in  general population due to increased prevalence of obesity and
diabetes.
Obesity is seen in 22.5% of people ?20 years of age .[17] Fatty liver
is found in >2/3  of the obese  people, irrespective of diabetes[18] and  >
90% in people with morbid obesity.[19] Steatohepatitis is seen in about
3% in lean population ,19% in obese population, and almost 50% in
morbid obesity people.[18,19]
Indian scenario:
Asian populations prevalence data are very less. Chitturi et al[21]
found the potential load of NAFLD in Asian-Pacific region as atleast
4,00,000 Australians and 1.8 million Asians had fatty liver. Prevalence of
fatty liver was found to be 15.8% and 24%, respectively in an autopsy
series from western India and from eastern coastal India .[22,23] Various
7studies in India found the insulin resistance and the metabolic syndrome
to be about 11- 41%[24] depending on the region and urbanization. In
Mishra et al[25] study metabolic syndrome and NAFLD are seen in  24%
and 14.8%, respectively, in  Indian non alcoholic men. In Mohan et al[26]
study NAFLD (54.5%) was found significantly higher in T2DM patients
than with pre-diabetic (33%), isolated IGT (32.4%), isolated IFG (27.3%)
and NGT (22.5%).In Gupte etal[27] study a symptomatic T2DM patients
had mild (65.5%), moderate (12.5%) and severe (9.35%)NAFLD
respectively. In Prashanth et al[28] study,T2DM patients had more
NAFLD and NASH which increased when components in the metabolic
syndrome increased . Banerjee et al[29] found on histology ,  fatty change,
NASH ,more advanced disease in43%,  40% and 23% respectively.
vikram et al[30]  showed, 1/3rd of the urban residents in metropolitan
Indian cities had metabolic syndrome. Insulin resistance is very high in
Asian Indians than white Caucasians.[31]
8Selected studies on prevalence of  NAFLD and NASH[20]
NAFLD Causes as listed below:[20]
9NAFLD Risk factors:(AASLD PRACTICE GUIDELINES 2012)
When severe obesity and diabetes present together, mild steatosis,
steatohepatitis and cirrhosis were seen in 100%, 50% and 19%
respectively.[32] Asians  have more visceral fat than their White
counterparts of the same BMI which is highly lipolytic and releases free
fatty acids directly into the portal vein.[33].Environmental factors and
lifestyle factors such as decreased physical exercise and high dietary fat
leads to insulin resistance and NAFLD..
PATHOGENIC MECHANISMS OF NAFLD:
NASH/NAFLD is a genetically determined disease due to its
association with diabetes and obesity.[34]Candidate genes in NASH are of
four types: Genes that in?uences steatosis severity, fatty acid oxidation,
oxidative stress,  effect of TNF. Insulin Resistance is the key pathogenic
factor for hepatic steatosis.
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FATTY ACID METABOLISM AND LIPOTOXICITY IN THE
PATHOGENESIS OF NAFLD/NASH[35]
Figure shows Factors involved in  triglyceride accumulation in the  liver
Day et alin 1998, gave the “two-hit-theory”[36],according to which,
first hit leads to hepatic steatosis due to Triglyceride accumulation in the
hepatocytes,  which results from abnormal  balance between formation,
supply,  consumption and hepatic disposal or oxidation of  Triglycerides.
Consumption means mitochondrial ß-oxidation of FFA, ketone bodies
production and secretion of  Triglycerides as VLDL particles When two
succeeding wallops delivered to the liver NASH occurs.
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NASH related Fibrogenesis:
Hepatic stellate cells (HSC)  are quiescent, vitamin A storing cells
have the ability to remodel during activation.HSC  are activated during
liver injury and resolution. When the liver is injured, HSC  activation
takes place, characterized by  change from quiescent to migrating
,proliferative, contractile and extracellular matrix (ECM) producing cells.
Fibrosis in NAFLD is a characteristic chicken-wire pericellular
distribution.[37]
12
Figure shows the mechanism of fibrogenesis in NASH
NATURAL HISTORY AND PROGNOSIS:
Less than 1% of patients with simple steatosis progressed to
cirrhosis or died from liver-related complication after a mean follow-up
of 15 years in a pooled analysis of several reported series. NASH  with
increased ?brosis, had worst prognosis  when compared with normal
population.[46]
The prevalence of cirrhosis and death related to liver complications
is about 11% and 7%, respectively, in patients with NASH during the ?rst
15 years of follow-up. Fbrosis, may remain stable for  many years or
actually improve or progresses over time in some cases [20]
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                   15–25%                                 30–40%
NASH                          CIRRHOSIS                         LIVER-RELATED
                                                                                                        DEATH
               Subacute              HCC           Recurrence after
failure                                      liver transplantation
[20]
Matteoni et al. [38]divided NAFLD into 4 types :
14
Figure below depicts Outcome of NAFLD based on Matteoni et al
types, proposed at the consensus conference in 1998.[38]
Figure below depicts the Factors involved in NAFLD development
and progression [39]
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CLINICAL MANIFESTATIONS AND DIAGNOSIS OF NAFLD:
Clinical presentations of  NAFLD patients can be any of the following[40].
Metabolic syndrome, .Abnormal liver function tests, Ultrasound
imaging of fatty liver, Fatigue, abdominal discomfort, Liver failure,
portal hypertension or liver cancer.
Reid et al noted an absence of specific symptoms in 48% to 100%
of patients.[41] Sanyal et al  noted fatigue in 45 of 62 patients(73%) and
right upper quadrant pain in 30 of 62(48%).[42]Moderate hepatomegaly
with right upper-quadrant tenderness may be present even up to 50% of
cases, but physical examination is generally unremarkable[1].
It is important to rule out the other possible causes of steatosis
other than NAFLD[1] like 1.Nutritional-Starvation,Malnutrition,Total
parenteral nutrition (TPN) 2.Infection-Hepatitis chronic C3.Systemic
disorders-Autoimmune hepatitis, Celiacdisease, IBD4.Medication/toxin-
Glucocorticoids,Amiodarone,Methotrexate,Valproic acid, Vitamin A,
Ethanol. 5.Inherited metabolic disorders-Wilson disease,a1pha 1-
antitrypsinde?ciency,Cystic?brosis,Glycogen storage disease.
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Biochemical abnormalities:
Elevations in AST and ALT is common but usually not more than
4 times the upper normal limit.AST/ALT ratio may be variable, usually
ALT predominates.[43,44] AST/ALT ratio >2  indicates alcoholic liver
disease but also occurs in advanced NAFLD. Isolated elevations in SAP
can also be seen.[45]
NON INVASIVE ANALYSIS OF NAFLD:
Several authors[47] proposed  different  noninvasive tools for
differentiating simple steatosis and NASH. NAFLD Fibrosis Score ,AST
to Platelet Ratio Index (APRI), BARD score , and FIB-4 are among the
more widely investigated noninvasive tools to cross-sectionally predict
advanced NAFLD. All are based on   clinical and laboratory variables
and each  of them exhibited varying degrees of accuracy.[53]
Pelekar et al.[48]used adiponectin,8-epi-PGF2?,hyaluronic acid, TGF-?,
and predicted NASH with 73.7%sensitivity,65.7%specificity, 68.2%
positive predictive value  and  68.2% negative predictive value.
Poynard et al.[49] in the Steato Test, used  biochemical markers such as
total bilirubin, ALT, GGT,haptoglobin,?2-macroglobulin,cholesterol,
apolipoprotein A-I, triglycerides, BMI, glucose, age and gender, that
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predicted steatosis in >30%  with 90% sensitivity and specificity,
93%NPV,  63% PPV.
Fibro Test[50] uses apolipoprotein A-I ,?2-macroglobulin (A2 M),
haptoglobin, total bilirubin, GGT, ALT and shows strong PPV (73%) and
NPV (90%)  for severe fibrosis, but can not differentiate fibrosis stages.
Hepascore uses Age, sex, bilirubin, GGT, hyaluronic acid, ?2-
macroglobulin.[51]
Harrison et al. [52] used three variables in BARD score (BMI ?28 kg/m2,
AST/ALT ratio ?0.8, and T2DM)in 827 patients with NAFLD and
showed96% NPV  and odds ratio of 17 to predict advanced fibrosis.
Of all scoring systems ,NAFLD-FS[53] received the most extensive
validation and  recommended for clinical use in the recent US multi
society practice guideline on the diagnosis and management of NAFLD.
NAFLD FIBROSIS SCORE:
Angulo et al. [46] formed a simple non-invasive scoring system
using clinical and laboratory variables to find whether advanced ?brosis
is present or not in NAFLD patients. This score  consists of Age,
hyperglycaemia, BMI, platelet count, AST/ALT ratio and albumin. It has
a strong PPV(82%) and NPV(93%)  for advanced NAFLD fibrosis .
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The NAFLD ?brosis score was calculated according to the following
formula:
When the calculated score is ?1.455=less probability of  ?brosis:
-1.455to  0.675=indeterminate:>0.675=high probability of  ?brosis.[4]
In   meta-analysis,  this  NAFLD  Score   was  found  to  have  an
AUROC of 0.85 in predicting advanced ?brosis .A score  of <1.455 had
90% and 60% sensitivity and speci?city respectively  to rule out
advanced ?brosis. A score > 0.676 had 67% and 97% sensitivity and
speci?city respectively to predict the  advanced ?brosis. The accuracy of
the NAFLD-FS  in separating patients’ risk for long-term outcomes can
be explained by the variables included in the scores[46].
Low albumin level  = indirect measurement of hepatic syn-thetic reserve
Low platelet count = more advanced liver disease and portal
hypertension.[55]
AST and ALT = good indicators of more advanced ?brosis and cirrhosis.
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Having low values of albumin and platelets and high AST/ALT
ratio or AST/platelet ratio will increase the scores, allowing the
identi?cation of patients with a higher risk for liver-related complications
and liver-related death or need for liver transplantation. Other variables
included in the scores, such as diabetes or hyperglycemia, older age, and
greater BMI are high risk factors for mortality from cardiovascular
disease and malignancy.
Stuart McPherson et al[47]found all scores  can  exclude advanced
fibrosis but the specificity of the NAFLD fibrosis scores, BARD score
and AST/ALT ratio was reduced if  patients ALT levels are normal (51%,
26% and 44% respectively) versus elevated ALT levels.
In order to reduce the number of patients undergoing liver
biopsy and for staging the disease, it is necessary to develop an algorithm
for investigating  NAFLD patients. These non invasive tests can be used
as  first-line  to rule out advanced fibrosis and more expensive tests as
second-line to diagnose advanced stage in patients with a high  NAFLD
fibrosis score.
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LIVER BIOPSY:
NAFLD is usually confirmed by  combining  history, laboratory
parameters and abdominal imaging. Liver biopsy is the best diagnostic
method to confirm and prognosticate NAFLD. Because of invasive
procedure it is impractical for widespread use.
NAFLD is characterized histologically with mixed micro and
macrovesicular steatosis, Mallory bodies, lobular inflammation,
ballooning degeneration, with or without perisinusoidal/perivenular
fibrosis. The pattern of fibrosis is characteristically chicken wire fencing
common to both Alcoholic and NAFLD hence distinguish from other
forms of liver disease.
Characteristic Findings of NAFLD in Liver-Biopsy.
Figure A:macrovesicularsteatosiswith inflammatory infiltrate,
hepatocyte ballooning and Mallory’s hyaline.
Figure B:  Masson’s trichrome staining showing  perivenular,
pericellular and perisinusoidal fibrosis in zone 3  “chicken wire” fibrosis.
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Grading of steatosis: (After Brunt )[78]
Grading of necroin?ammation.: (After Brunt)[78]
Staging of ?brosis:
IMAGING
Ultrasound
Ultrasound is the least expensive and easily available modality for
imaging liver. Its accuracy for identifying steatosis decreases when the
liver fat content is < 30%. The steatosis in ultrasound is shown as an
increased echo texture, or a ‘‘bright’’ liver. In Saadeh et al. study the
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ultrasound and computed tomography scan showed 100% and 93%%,
sensitivity  with 62% and 76% PPV and NPV respectively.[56]
In one study among the 187 obese patients who underwent bariatric
surgery, steatosis was diagnosed by ultrasound with 49.1% and 75%
sensitivity and specificity.[57]
Palmentieri et al.[58] in his study conducted among  235 patients
who underwent ultrasound with liver biopsy found  ‘‘bright liver’’ pattern
on  ultrasonography  with91%, 93%, 89%, and 94%,sensitivity,
specificity, PPV and NPV respectively, to diagnose >30%steatosis.
Hepato-renal contrast (discrepancy in the echogenesity between liver and
renal parenchyma) was more precise in differentiating  steatosis from
fibrosis.[59]If the liver parenchyma is not infiltrated with fat, its
echotexture is as same as renal parenchyma, but when fat infiltration is
present it becomes ‘‘brighter’.[60]  .
FIGURE: ULTRASOUND GRADING OF LIVER STEATOSIS :[63]
A :NORMAL, B: Grade 1(mild),C:Grade 2(moderate), D:Grade
3(severe)
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In 93 chronic liver disease patients  who had undergone liver
biopsy Webb et al.[61] found that the hepatorenal index can grade the
steatosis severity to5% lower limit.
Iijima et al.[62] used an contrast agent in ultrasound (Levovist -
Sherling, Berlin) to identify NASH. Galactose and palmitic acid in
Levovist will be taken up by normal hepatocytes because they participate
in metabolism of sugar and fat. If reduced uptake then NASH is
diagnosed.
Doppler perfusion index (DPI)is a ratio of arterial blood flow to
total blood flow in liver. When steatosis is present the liver
hemodynamics are altered[64].NAFLD was found to have valtered DPI in
many series.[65,66,67]
Computerised tomography:
Piekarski et al in his study[68]  measured in normal subjects  the
non contrast CT numbers. Lower CT numbers are found in fatty livers.
Park et al. [69] identified steatosis in 154 patients who have undergone
liver biopsy using non enhanced CT. They used liver-to-spleen
attenuation ratio and difference for identifying >30%steatosis and
showed100%specificity 73% to 82% sensitivity. Osawa and Mori[60]
detected steatosis using hepato-renal difference in  CT scan  with 91.3% ,
83.8% , 86.7% -sensitivity, specificity and accuracy.
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Lee et  al.[70] used both nonenhanced CT scans and liver-to-spleen
attenuation and proved both of them have equal efficacy in diagnosing
>30% steatosis. Non contrast is  better than contrast-enhanced CT scan
for  identifying hepatic steatosis. [71]
Magnetic resonance imaging(MRI):
Fatty changes in MRI is assessed from  chemical shifts difference
in between fat and water. Fishbein et al. [72]correlated histology,
ultrasound, and MRI in NAFLD patients and showed MRI was able to
accurately detect 3%. Steatosis.
MRS[73]  Proton magnetic resonance spectroscopy  is  a  MRI
variant,  found to accurately measure steatosis. Szczepaniak et al.[74]
utilised proton MRS in 375 subjects and measured hepatic triglyceride
levels (HTGC) and found 34.3% had HTGC>5%,  diagnostic level for
hepatic steatosis. Browning et al.[75] by using this found37.6% steatosis in
his population.
Figure showing CT
SCAN image of fatty liver
with low attenuation of
liver when compared to
spleen
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Magnetic resonance elastography (MRE): A  mechanical wave
is generated and MRI scans are used to measure the displacement in the
liver, which are converted to a elasticity measure.[76]Yin  et  al. [77] used
MRE and showed in 85 patients  this scan was able  separatestage 0–1
fibrosis from stage 2–4 fibrosis with 86% sensitivity and85% specificity.
MRI  and  MRS  detects  subtle  fat  changes   more  accurately  than  CT or
ultrasound but limited due to high cost and less accessible.
Overview and developments in noninvasive diagnosis of nonalcoholic
fatty liver disease
Routine laboratory tests
   Liver enzymes
   Parameters of liver dysfunction
Imaging methods
   Ultrasound
   Computed tomography
   Magnetic resonance imaging
   Magnetic resonance elastography
Liver stiffness measurement
   Transient elastography
(FibroScan)
Acoustic radiation force impulse
imaging
Multicomponent tests for
diagnosis of non-alcoholic
steatohepatitis
   Nash test
   Non-alcoholic steatohepatitis
clinical scoring system for morbid
obesity
Biomarkers of necroinflammation
Cytokeratin 18 fragments
   High-sensitivity C-reactive
Protein ,   Interleukin-6,
C-C chemokine ligand 2
   Plasma pentraxin 3,
 Oxidative stress measurement,
Tumor necrosis factor-a
Adiponectin,
Insulin resistance measurement.
Multicomponent panels for
diagnosis of fibrosis
Fibrotest, Non-alcoholic fatty liver
disease fibrosis score,   European
liver fibrosis panel/enhanced liver
fibrosis panel.
Biomarkers of fibrosis
   Hyaluronic acid,   Laminin
   Type?collagen 7S domain
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LIVER STIFFNESS (LS) MEASUREMENT :
Liver stiffness(LS) is named as Young’s modulus or  the modulus
of elasticity[79]based on the principles of Hooke’s law of elasticity,
expressed in kilopascals (kPa) and shows the resistance of  the liver to
deformation.LS, depends on many factors-1.extracellular matrix,
2.constraints or pressure applied,3internal pressure inside the liver,
3.viscous effects.
TRANSIENT ELASTOGRAPHY (FIBROSCAN):
Fibroscan is a non-invasive ultrasound technique[80which is
painless, and quick (5–10 min) method for measuring liver stiffness,
which is positively correlated with the ?brosis degree .[81,82,83]
Basic principles:
TE is based on the principle of Hooke’s law(strain response of the
material to external stress) . A transducer probe (ultrasound) is mounted
on the vibrator axis which delivers vibrations of low frequency (50
Hz)and low amplitude . The transducer transmits the vibrations from a
right intercostal space. Elastic shear wave  are produced  propagates
through the liver and the speed  of propagation is measured using Pulse-
echo ultrasound. This speed is proportional to the stiffness of the tissue,
with faster wave progression occurring through stiffer material.[85].
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Fibroscan measures LS as a cylindrical volume in  1cm wide and
4cm long, between 2.5 and 6.5 cm beneath the skin surface with the
standard M-probe, and between 3.5 and 7.5 cm for the recently developed
XL probe, recommended for obese patients[86,87]. It is at least 100 times
larger than a  liver biopsy sample and results, are more representative of
the hepatic parenchyma.
TE does not work for the left liver lobe or from a subcostal
approach and the measurement is only feasible via a few intercostal
spaces. Therefore, the technique is limited. Inter- and intra-observer
variability depend on the intercostal space used, the presence of  ascites,
musculoskeletal habitus, depth of  subcutaneous tissue, position of  the
patient, and many other factors[88].
Performing the Technique:[84]
The measurements with FibroScan  are taken via an intercostal
space from the right lobe of liver. Patient lies  supine and the right arm
kept behind the head. The probe tip is covered with coupling gel and
placed over the skin in between the ribs at the  right lobe level. Once the
area is located, the operator presses the  shot button to start acquisition.
The machine will not give reading for an unsuccessfull shot. LS is
expressed in kilopascals (kPa) in a range from 2.5 and 75 kPa.
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Figure A:Fibroscan monitor, B:Measurement in Normal liver,
             C:Cirrhosis
Advantages:
Rapid procedure (less than 5 min), painless, results are
immediately available. Easy to perform in outpatient clinic or at the
bedside within a short learning period (100 examinations). Excellent
inter- and intra-observer agreement, which makes it suitable for
widespread application in clinical practice.
Liver Stiffness Evaluation (LSE) Criteria:[80]
LSE is the median of the 10successful stiffness values measured.
LSE ranges from lowest stiffness 2.5 kPa to highest stiffness 75 kPa. LSE
failure is termed, if with even 10 attempts no  measurements are obtained.
Success rate is calculated as the number of successful measurements
divided by total numbers attempted (expressed in %).  LSE is valid only
if all three, ?10 measurements are successful ,?60% success rate ,
IQR/median ratio <0.30 are achieved.
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The validity depends on 2 parameters, the success rate and  the
interquartile range (IQR). Both  feasibility and reproducibility of  the TE
measurement may be affected by high body mass index (BMI). failure
rate of  3.1% was reported and Unreliable results were reported in 15.8%
of  measurements and were associated with a BMI > 30 kg/m, age>  52
years, female sex, operator experience and type 2 Diabetes.
LS measurement outscores all noninvasive methods in identifying
advanced fibrosis and  cirrhosis. LS < 6 kPa  is  normal and excludes
ongoing liver disease. LS between 8 and 12.5 kPa is the cut-off values to
detect F3 and F4 fibrosis.LS >20 kPa highly correlates with development
of portal pressure, and Esophageal varices.LS is also increased by tumor
cells, amyloidosis, mast cells and inflammatory cells, cholestasis, liver
congeston.
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In biopsy-proven 27NAFLD patients ,Takeda et al [89]compared
Fibro-Scan liver stiffness values with Brunt fibrosis score and found LS
was much higher with stage 3 or 4 fibrosis patients than with lower
stages.
In 135 biopsy-proven NASH patients, Fukuzawa et al.[90]
measured LS and found liver elasticity can accurately predict fibrosis and
distinguish patients within each of the Brunt fibrosis stages (F0-1, F2, F3
and F4).
OTHER TECHNIQES FOR LIVER STIFFNESS
MEASUREMENTS:[80]
? ACOUSTIC RADIATION FORCE IMPULSEIMAGING(ARFI):
Acoustic pulses  of Short-duration and 2.67 MHz fixed transmit
frequency, are generated in the ROI (Region Of Interest).This causes
mechanical excitation in  the tissues  and shear waves are formed  due to
tissue displacement and  propagate away from the region of  excitation.
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Ultrasound tracking beams laterally adjacent   to the single push beam are
used to estimate the shear wave speed in the tissue by  measuring the time
to peak displacement with each lateral location.[91]
The accuracy of    ARFI  and TE has been shown to be similar  in
the differentiation of  normal liver parenchyma from liver cirrhosis. ARFI
has a significant advantage over TE in that it simultaneously displays a
conventional ultrasound image. ARFI allows different measurement sites,
comparison of  measurements in the right and left liver lobes have been
made, results in the right lobe revealed higher diagnostic accuracy
compared to the left[92]. ARFI has also been evaluated in patients with
NAFLD and NASH[93,94]  and in patients after liver transplantation.
? 2D SWE(2D-SHEAR WAVE ELASTICITY):
2D SWE is formed by the combination of   radiation force produced in
the tissues by focused ultrasonic beams with very high frame rate ( 5000
f/s) ultrasound imaging able to catch ,the resulting transient shear waves
propagation [95,96]in real time.
Comparison of various techniques to assess liver stiffness[79]
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Liver stiffness (LS) is a surrogate marker for fibrosis
stage:[79]
LS correlates accurately with fibrosis stage (r> 0.7 and P<0.005).
LS can identify F3fibrosis andF4cirrhosis  with high accuracy (AUROC
>0.9) whereas F1 and F2 Fibrosis stages only mildly increase the LS.
Despite some variability, cut-off values of 8.0 and 12.5 kPa are widely
accepted to identify patients with F3 and F4 fibrosis, respectively.
ALGORITHM FOR NON INVASIVE DIAGNOSIS AND STAGING
IN NAFLD: [6]
An algorithm is proposed for non invasive diagnosis and
management of NAFLD patients in a recent published article by
Dowman et al[6].
In that article, if fatty liver is identified by USG then using the
clinical and laboratory data the NAFLD ?brosis score  is calculated. If
the score is below the lower cut-off level then these patients are at low
risk of signi?cant ?brosis and are managed safely in primary care.
If  the score  is  indeterminate or high they should be referred for
specialist care. They are further subjected to further  investigations such a
fibroscan or serum markers panel to identify the risk of fibrosis and
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staging. Liver biopsy should only be done in  those patients where the
non-invasive test results  are inconclusive.
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MATERIALS AND METHODS
Source:
For the study, consecutive T2DM patients attending diabetic
outpatient clinic in the Stanley medical college Hospital between April
2013 and March 2014, will be evaluated on the basis of clinical,
biochemical, ultrasonographic findings .
Inclusion criteria:
1. All the patients with atleast ,  one year history of T2DM, were  on
oral hypoglycaemic agents and/or insulin injections.
2. Age between 25-65 yrs.
Exclusion criteria:
1. An alcohol ingestion >30 grams/day in males ,>20 grams/day in
females.
2. History suggesting chronic liver disease with any etiology,
3. History of any severe disease such as malignancy,
4. Intake of drugs known to cause fatty liver disease -steroids,
synthetic estrogens, heparin, calcium channel blockers,
amiodarone, valproic acid, antiviral agents
5. History of any parenteral nutrition
6. Hereditary disorders and inborn errors of metabolism
7. Starvation
8. Acute fatty liver of pregnancy, HELLP Syndrome
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STUDY DESIGN: This is a prospective study conducted in diabetic
patients.
All patients fulfilling the inclusion criteria during the study,
history, anthropometry and physical examination were done and recorded
accordingly, after taking informed consent of the patient. This study  was
approved by the Institutional Ethical Committee. All patients in the study
had undergone routine investigation including complete blood counts,
blood sugar, liver function test, HbsAg, Anti HCV, and  fasting Lipid
Profile.
Abdominal girth measurements were taken midway between
umbilicus and lower costal margin and blood pressure measured in sitting
posture in both the upper limbs.
Metabolic syndrome was diagnosed as per NCEP ATP 3 criteria[7] -
three or more of the following,
1. Waist circumference :Males: >90cms, Females: > 80cms
2. Fasting glucose?100mg%
3. Hypertension(mm/hg)> 130/85 mmHg
4. High triglycerides (mg/dl) ? 150mg/dl
5. Low HDL(mg/dl) : in Males: < 40 mg/dl, in Females: < 50
mg/dl
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This also includes patients diagnosed previously with
hypertension, high TGL, low HDL, IFG, IGT or T2DM, and those were
already on treatment for these disorders.
NAFLD is detected by means of ultrasonography done by  single
experienced radiologist, using a B-mode ultrasonography ,high-resolution
system with an electric linear transducer mid frequency of 3–5 MHz .An
increase in hepatic echogenicity is noted .The enhancement and
differential loss in the periportal intensity and the vascular wall due to
increased  hyperechogenicity in the liver parenchyma is also noted. The
degree of involvement was standardised with  semi quantitative scale for
the degree of hepatic involvement.[8]
Grade  1: Diffuse increase in the fine echoes slightly. Liver is bright
compared to the cortex of the kidneys are visualised normally.
Grade  2: moderately diffuse increase in fine liver echoes, mild
impairment in visualisation of Intrahepatic vascular borders and
diaphragm .
Grade  3: markedly increased liver fine echoes, Intrahepatic vessel
borders, diaphragm and the vessels not visualised.
 NAFLD was suspected if there is abnormal liver biochemistry, bright
liver on ultrasound and no known causes identified for the liver disease.
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Diagnosed NAFLD patients were subjected to NAFLD ?brosis
score calculated according to the following formula using Online
calculator(www.nafldscore.com) given by Angulo P, Marchesini G et al.
Based on the score, if the value obtained is between -1.455 and
0.676 or >0.676 intermediate risk or high risk patients are identified.
Those patients with grade 2 and 3 fatty liver by ultrasound with NAFLD
Fibrosis score (indeterminate and high risk)  are refered for liver stiffness
evaluation with fibroscan.
Transient Elastography (Fibroscan -manufacturer: Echosens, Paris,
France) done in department of hepatology at Madras medical college, by
single experienced personal, as per the manufacturer’s recommendations,
with the patient  in supine position  and right arm over the head.
Transducer probe (M Probe or XL probe) tip is coated with coupling gel
and placed over the skin in between the ribs focussing towards the right
lobe of  liver. When a suitable target area had been located, several
attempts  made to collect minimum 10 valid measurements from a depth
of 25 mm to 65 mm below the skin surface.
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The success rate (SR) , median liver stiffness value (kPa), and
ratio of  interquartile range (IQR) of liver stiffness  to  median (IQR/M)
were calculated.
Examinations with < 10 valid measurements, SR of < 60% and/or
an IQR/M ? 30% were considered to be unreliable.
Fibroscan -manufacturer:Echosens, Paris, France
Liver stiffness measurements are done over the right lobe of  liver in
intercostal space  using A) A-mode and B) M-mode images to locate the
liver. Shear wave velocity is derived from C) elastogram ( strains induced
in the liver due to shear wave propagation as a function of time and
depth.
39
The  results of the fibroscan are interpreted as follows
Based on these values a correlation is made between ultrasound
grading of fatty liver, NAFLD Fibrosis score and fibroscan liver stiffness
to identify patients who merits for invasive liver biopsy to decide on
further treatment protocol.
STATISTICAL ANALYSIS
Statistical  data analysis was conducted with  SPSS, version 17.0
(SPSS, Inc. Chicago, IL, USA). Continuous variables were expressed in
mean ± standard deviation (SD). Qualitative data were represented as
numbers, with the percent ages indicated within parentheses. The
statistical signi?cance of differences in the quantitative data were
determined using the one way ANOVA and categorical variables were
compared with CHI SQUARE test. P value of < 0.05 was considered a
statistically significant difference.
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OBSERVATION AND RESULTS
In this study a total of 567  patients were screened out of which
500 patients satisfied the inclusion criteria and were analysed as per the
flow diagram.
FLOW DIAGRAM  1:
TOTAL DIABETICS
SCREENED N =567
NON-NAFLD
N = 181
USG ABDOMEN
FATTY LIVER
67  EXCLUDED
5   = HBSAG POSITIVE
13 = HYPOTHYROIDISM
9 = ANTI-EPILEPTIC DRUGS
40 = ALCOHOL INGESTIONTOTAL ELIGIBLE
N = 500
NO
NAFLD
N = 319
YES
N = 67
HIGH >0.676
(H) N=24
NAFLD
FIBROSIS
SCORE
INTERMEDIATE
-1.455 to 0.676
(I) N=164
LOW <-1.455
    N=131
FATTY LIVER
GRADE-1 N= 123
FATTY LIVER
(G2)GRADE-2 N= 163
FATTY LIVER
(G3) GRADE-3 N= 33
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A total of 184 patients who had grade 2 and 3 fatty liver with
intermediate and high NAFLD risk score were selected and subjected to
fibroscan estimation of liver stiffness. In 84 patients fibroscan  was not
done  and the results were analysed  only for 100 patients as follows.
FLOW DIAGRAM 2:
FIBROSCAN ,  N =184
LIVER STIFFNESS (kPa)
Grade2-FL+High Score     = 85
Grade3-FL+High Score     = 17
Grade2-FL+Intermediate score =  66
Grade3-FL+Intermediate score = 16
         LS
    >12.5  kPa
       N=5
         LS
    8 – 12.5 kPa
         N=40
LS  6 - 8 kPa
    N=39
 LS < 6 kPa
     N=16
NOT DONE, N=84
DONE , N=100
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TABLE NO.1
DISTRIBUTION OF GRADES OF FATTY LIVER BASED ON
ULTRASOUND
NAFLD BY
ULTRASOUND
TOTAL(n=70) PERCENTAGE (%)
NO FATTY LIVER 181 36.2
GRADE I 123 24.6
GRADE II 163 32.6
GRADE III 33 6.6
Of the total 500 patients 319(63.8%)had fatty liver[NAFLD] and
181(36.2%) had no fatty liver[NON NAFLD].Among the NAFLD
patients 38.5%, 51 % and 10.3% had grade I,  grade II and  grade III fatty
liver  as diagnosed by ultrasound.
181, 36%
123, 25%
163, 33%
33, 6%
FATTY LIVER GRADE
NO
GRADE 1
GRADE 2
GRADE 3
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TABLE NO.2
AGE DISTRIBUTION OF NAFLD AND NON NAFLD PATIENTS
Age group
(years)
NAFLD(USG)
Total
(n=319) %
NON
NAFLD
Total
(n=181)%
Grade I
(n=123)
Grade II
(n=163)
Grade III
(n=33)
26-35 5 5 3 13(4.07%) 3(1.6%)
36-45 24 23 5 52(16.3%) 40(22.1%)
46-55 42 57 7 106(33.2%) 74(40.9%)
56-65 41 53 16 110(34.4%) 48(26.5%)
66-75 11 25 2 38(11.9%) 16(8.8%)
In this study the majority of patients are in the age group of 56-65
years and 46-55 years in NAFLD and non NAFLD group respectively.
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26-35 36-45 46-55 56-65
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GRADE 2
GRADE 3
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TABLE NO.3
GENDER DISTRIBUTION OF NAFLD AND NON NAFLD
PATIENTS
Sex
NAFLD(USG)
Total
(n=319)%
NON-NAFLD
Total(n=181)
%
Grade I
(n=123)
Grade II
(n=163)
Grade III
(n=33)
Male 22 25 7 54(16.9%) 37(20.4%)
Female 101 138 26 265(83.1%) 144(79.6%)
          In this study majority are females i.e. 265 out of 319(83.1%)   in
NAFLD group and 144 out of 181(79.6%) in Non NAFLD group.
0
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NAFLD NON NAFLD
MALE
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TABLE NO.4
AGE DISTRIBUTION AMONG NAFLD FIBROSIS RISK SCORE
AGE
GROUP
IN YRS
                      RISK OF FIBROSIS TOTAL Pearson
Chi-
Square
Value
38.201(a)
df = 8
P VALUE
<0.001
LOW INTERMEDIATE HIGH
26-35 3 10 0 13
36-45 3 35 14 52
46-55 12 56 38 106
56-65 6 53 51 110
66-75 0 10 28 38
TOTAL 24 164 131 319
The above table shows most of the patients with intermediate and
high NAFLD score were in the age group of 46-65 years. As the age
advances, the risk of fibrosis increases with a highly significant P
value(0.00).
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TABLE NO.5
DISTRIBUTION OF METABOLIC SYNDROME AMONG NAFLD
AND NON NAFLD PATIENTS
VARIABLES
NAFLD
(N=319)%
NON
NAFL
D
(N=18
1)%
GRADE I
N=123
GRADE
II
N=163
GRADEIII
N=33
 BP>135/85 PRESENT 17 62 18 12
ABSENT 106 101 15 169
CENTRAL
OBESITY
PRESENT 101 156 31 125
ABSENT 22 7 2 56
LOW HDL
PRESENT 44 84 27 33
ABSENT 79 79 6 148
HYPERTRIG
LYCERIDIM
IA
PRESENT 37 156 31 32
ABSENT 86 7 2 149
METABOLI
C
SYNDROME
PRESENT 16 156 31 28
ABSENT 77 7 2 153
From the above table, metabolic syndrome is found in 73% of the
NAFLD patients whereas in non NAFLD patients only 15.4%. Among
the NAFLD patients Grade 1- 13%,  Grade 2- 95.7%,  Grade 3- 93.93%
had metabolic syndrome
By applying CHI square test P value was <0.001 highly significant.
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TABLE NO.6
DISTRIBUTION OF BMI AMONG NAFLD AND NON NAFLD
PATIENTS
   BMI
                        NAFLD (N=319)
NON NAFLD
   (N=181)
GRADE   I
   (N=123)
GRADE II
   (N=163)
GRADE III
   (N=33)
<18.5 0(0%) 0(0%) 0(0%) 7(3.86%)
18.5-22.9 19(15.4%) 10(6.13%) 0(0%) 59(32.6%)
23-24.9 17(13.8%) 25(15.33%) 4(12.1%) 43(23.7%)
25-29.9 70(56.9%) 66(40.5%) 11(33.3%) 60(33.1%)
>30 17(13.8%) 62(38.03%) 18(54.5%) 12(6.6%)
In NAFLD and non NAFLD cases the mean BMI was 28.04±4.12
kg/m2and 24.44±3.08 kg/m2.The mean BMI among the NAFLD cases
were Mean BMI (kg/m2):Grade I-26.65±3.4
                                   Grade II-28.51±4.05
                                  Grade III-30.92±4.96
46 out of 319(14.4%) of NAFLD patients were overweight(BMI=23-
24.9),147 out of 319 (46.08%) were moderately obese (BMI=25-29.9)
and 97 out of 319 (30.4%) patients were severely obese (BMI>30).There
was statistical significance (P<0.001) when comparing the means within
the NAFLD cases using ANOVA.
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TABLE NO.7
CLINICAL AND BIOCHEMICAL PROFILES OF ALL CASES OF
NAFLD AND NON NAFLD
VARIABLES                    NAFLD (N=319)   NON
NAFLD
 (N=181)
GRADE I
   (N=123)
GRADE  II
   (N=163)
GRADE  III
   (N=33)
ABDOMINAL PAIN 32 100 18 43
FATIGUE 30 105 15 32
MALAISE 14 54 7 26
HEPATOMEGALY 3 25 22 12
ASYMPTOMATIC 51 64 10 37
AGE 53.74 55.40 54.06 52.65
BMI 26.65 28.51 30.92 24.44
PLATELETS 208.63 199.82 212.12 224.97
AST 32.60 32.51 34.21 30.27
ALT 24.46 23.04 25.18 22.87
ALBUMIN 4.04 3.94 3.66 4.06
By comparing  the mean of clinical and laboratory data in the
NAFLD patients within different grades of fatty liver and with
NON NAFLD patients, variables such as BMI, platelets and serum
albumin were found to have significant  difference .P value. AST was
always higher than ALT in all grades. AST to ALT ratio was  >1.
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TABLE NO.8
DISTRIBUTION OF NAFLD FIBROSIS RISK SCORE WITH
GRADES OF FATTY LIVER
RISK OF
FIBROSIS
   USG ABDOMEN GRADE (NAFLD) TOTAL
N=319GRADE I
   (N=123)
GRADE II
   (N=163)
GRADE III
   (N=33)
LOW 12(9.7%) 12(7.36%) 0(0%) 24(7.53%)
INTERMEDIATE 82(66.6%) 66(40.5%) 16(48.48%) 164(51.41%)
HIGH 29(23.6%) 85(52.14%) 17(51.51%) 131(41.06%)
The above chart shows most of the NAFLD patients are in the
intermediate (164/319 = 51.41%) and high risk(131/319 = 41.06%) for
NAFLD fibrosis score. The risk increases as the grade of the fatty liver
increases.
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TABLE NO.9
AGE DISTRIBUTION AMONG RISK OF FIBROSIS
Age group
(years)
RISK OF FIBROSIS
Total
(n=319) %
LOW
(n=24)
INTERMEDIATE
(n=164)
HIGH
(n=131)
26-35 3(12.5%) 10(6.1%) 0 13(4.07%)
36-45 3(12.5%) 35(21.3%) 14(10.7%) 52(16.3%)
46-55 12(50%) 56(34.1%) 38(29%) 106(33.2%)
56-65 6(25%) 53(32.3%) 51(38.9%) 110(34.4%)
66-75 0 10(6.1%) 28(21.4%) 38(11.9%)
From the above table, majority of  patients with
Low score are in the age group of 46-55yrs (50%)
Intermediate score are in the age group of 56-65 yrs(34.1%)
High score are in the age group of 56-65 yrs(38.9%).
By applying CHI Square test P value <0.001 highly significant.
Higher the age, higher the NAFLD fibrosis risk score.
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TABLE NO.10
COMPARISION OF THE COMPONENTS OF THE NAFLD
FIBROSIS SCORE WITH GRADES OF FATTY LIVER
PARAMETERS USGABDOMEN N Mean
Std.
Deviation
ANOVA
Within and
between
groups
Age in years Grade I 123 53.74 9.566
0.342
Grade II 163 55.40 9.738
Grade III 33 54.06 10.458
Total 319 54.62 9.750
BMI Grade I 123 26.651 3.4032
<0.001
Grade II 163 28.516 4.0529
Grade III 33 30.924 4.9677
Total 319 28.046 4.1255
Platelet(10^9/L) Grade I 123 208.63 58.070
0.335
Grade II 163 199.82 60.667
Grade III 33 212.12 52.187
Total 319 204.49 58.878
AST Grade I 123 32.60 12.601
0.784
Grade II 163 32.51 13.513
Grade III 33 34.21 11.736
Total 319 32.72 12.964
ALT Grade I 123 24.46 10.764
0.521
Grade II 163 23.04 14.642
Grade III 33 25.18 8.647
Total 319 23.81 12.722
Sr.Albumin Grade I 123 4.040 .6927
0.013
Grade II 163 3.940 .6140
Grade III 33 3.667 .6333
Total 319 3.950 .6542
Nafld Fibrosis
Score
Grade I 123 -.015327 .9814194
<0.001Grade II 163 .456294 1.0479672
Grade III 33 .580455 .9533483
Total 319 .287291 1.0389617
The above table shows the NAFLD fibrosis score (P value <0.001),
BMI (P value <0.001) and albumin(P value = 0.013) were  statistically
significant when compared within and between the groups using one way
ANOVA.
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TABLE N0.11
COMPARISION OF NAFLD SCORE COMPONENTS WITHIN
AND BETWEEN LOW, INTERMEDIATE AND HIGH RISK
GROUPS
PARAMETERS NAFLD SCORE N Mean Std. Deviation
ANOVA Within
and between
groups
Age in years Low 24 49.92 8.997
<0.001
Intermediate 164 52.41 9.710
High 131 58.25 8.743
Total 319 54.62 9.750
BMI Low 24 26.755 4.0139
0.072
Intermediate 164 27.798 4.0325
High 131 28.592 4.2080
Total 319 28.046 4.1255
Platelet(10^9/L) Low 24 307.08 59.233
<0.001
Intermediate 164 217.79 49.047
High 131 169.05 37.561
Total 319 204.49 58.878
AST Low 24 22.54 7.638
<0.001
Intermediate 164 31.92 13.297
High 131 35.59 12.282
Total 319 32.72 12.964
ALT Low 24 22.71 8.715
       0.211
Intermediate 164 25.03 15.923
High 131 22.48 7.791
Total 319 23.81 12.722
Sr.Albumin Low 24 4.642 .3775
<0.001
Intermediate 164 4.017 .6233
High 131 3.740 .6292
Total 319 3.950 .6542
Nafld Fibrosis
Score
Low 24 -1.972592 .5512643
<0.001Intermediate 164 -.137598 .5163673
High 131 1.233237 .4243921
Total 319 .287291 1.0389617
When compared the individual components of the NAFLD fibrosis
score within and between the various grades of the score(low,
intermediate, high) using ANOVA it is found that BMI, platelet count,
AST, albumin, NAFLD Score were statistically significant (P value
<0.001).
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TABLE N0.12
FREQUENCY DISTRBUSION OF FIBROSCAN LIVER
STIFFNESS
Liver stiffness in
kPa Frequency Percent
Valid
Percent
Cumulative
Percent
Valid < 6 16 3.2 16.0 16.0
6-8 39 7.8 39.0 55.0
8-12.5 40 8.0 40.0 95.0
> 12.5 5 1.0 5.0 100.0
Total 100 20.0 100.0
Missing 400 80.0
                   Total 500 100.0
From the above table
16%were in the category of <6 kPa, low risk for fibrosis
39% were in the category of 6-8 kPa ,gray zone for fibrosis
 40% were in the category of 8-12.5 kPa,F-3 fibrosis
5%were in the category of >12.5 kPa,F-4 fibrosis.
16, 16%
39, 39%
40, 40%
5, 5%
FIBROSCAN LIVER STIFFNESS GRADE
<6 kPa
6-8 kPa
8-12.5 kPa
>12.5 kPa
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TABLE NO.13
AGE DISTRIBUTION AMONG FIBROSCAN LIVER STIFFNESS
Age group
(years)
 FIBROSCAN GRADE OF LIVER STIFFNESS    Total
(n=100)
%<6 kPa
N=16
6-8 kPa
N=39
8-12.5 kPa
N=40
>12.5 kPa
N=5
26-35 1 2 1 0 4
36-45 5 7 6 2 20
46-55 5 10 17 1 33
56-65 4 15 13 2 34
66-75 1 5 3 0 9
The above table shows the distribution of the liver stiffness values
of the fibroscan in various age groups. Among 100 patients who
underwent fibroscan majority  of them that is 33% and 34% were in the
age group of 46-55 years and 56-65 years respectively.
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TABLE NO.14
DISTRIBUTION OF COMPONENTS OF METABOLIC
SYNDROME AND NAFLD FIBROSIS SCORE
VARIABLES
NAFLD FIBROSIS SCORE
(N=319)%
LOW
(n=24)
INTERMEDIATE(
n=164)
HIGH (n=131)
      BP>135/85 PRESENT 4(4.1%) 47(48.5%) 46(47.4%)
ABSENT 20(9%) 117(52.7%) 85(38.3%)
CENTRAL
OBESITY
PRESENT 19(6.6%) 146(50.7%) 123(42.7%)
ABSENT 5(16.1%) 18(58.1%) 8(25.8%)
LOW HDL
PRESENT 10(6.5%) 74(47.7%) 71(45.8%)
ABSENT 14(8.5%) 90(54.9%) 60(36.3%)
HYPERTRIGLY
CERIDIMIA
PRESENT 13(5.8%) 105(46.9%) 106(47.3%)
ABSENT 11(11.6%) 59(62.1%) 25(26.3%)
METABOLIC
SYNDROME
PRESENT 14(6%) 108(46.4%) 111(47.6%)
ABSENT 10(11.6%) 56(65.1%) 20(23.3%)
When comparing the risk of fibrosis with various components of
metabolic syndrome and by applying CHI Square test hypertrigly-
ceridemia is statistically significant (p = 0.001) overall metabolic
syndrome was found to have highly significant P value (<0.001).
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TABLE NO.15
COMPARISION OF GRADES OF FATTY LIVER WITH GRADES
OF LIVER STIFFNESS (FIBROSCAN)
UsgAbd-Fatty Liver Grade
Fibroscan Findings (Liver Stiffness in
kPa)
Total
Pearson
Chi-
Square
Value=
4.410(a)
Df   = 3
P VALUE
0.220
< 6 6-8 8-12.5 > 12.5
Grade II Count 13 28 24 2 67
% within
UsgAbd-Fatty
Liver Grade
19.4% 41.8% 35.8% 3.0% 100.0%
% within
Fibroscan
Findings (Liver
Stiffness in kPa)
81.3% 71.8% 60.0% 40.0% 67.0%
Grade III
Count 3 11 16 3 33
% within
UsgAbd-Fatty
Liver Grade
9.1% 33.3% 48.5% 9.1% 100.0%
% within
Fibroscan
Findings (Liver
Stiffness in kPa)
18.8% 28.2% 40.0% 60.0% 33.0%
Total Count 16 39 40 5 100
% within
UsgAbd-Fatty
Liver Grade
16.0% 39.0% 40.0% 5.0% 100.0%
% within
Fibroscan
Findings (Liver
Stiffness in kPa)
100.0% 100.0% 100.0% 100.0% 100.0%
A total of 100 patients were subjected to fibroscan among  which
67 patients and 33 patients were in grade II and grade III respectively .By
applying CHI square test ultrasound grades of fatty liver do not correlate
with the fibroscan liver stiffness (P Value = 0.220).
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TABLE NO.16
COMPARISION OF NAFLD FIBROSIS SCORE AND
FIBROSCAN  LIVER STIFFNESS
Risk of Fibrosis Fibroscan Findings
 (Liver Stiffness in kPa) Total
Pearson
Chi-
Square
Value
11.589(a)
Df = 3
P
VALUE
0.009
< 6 6-8 8-12.5 > 12.5
Intermedia
te
Count 12 21 15 0 48
% within Risk of
Fibrosis 25.0% 43.8% 31.3% .0% 100.0%
% within Fibroscan
Findings (Liver
Stiffness in kPa)
75.0% 53.8% 37.5% .0% 48.0%
High
Count 4 18 25 5 52
% within Risk of
Fibrosis 7.7% 34.6% 48.1% 9.6% 100.0%
% within Fibroscan
Findings (Liver
Stiffness in kPa)
25.0% 46.2% 62.5% 100.0% 52.0%
Total Count 16 39 40 5 100
% within Risk of
Fibrosis 16.0% 39.0% 40.0% 5.0% 100.0%
% within Fibroscan
Findings (Liver
Stiffness in kPa) 100.0% 100.0% 100.0% 100.0% 100.0%
By applying CHI Square test,  indeterminate and high risk score correlate
with      high liver stiffness value (P = 0.009).
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TABLE NO.17
COMPARISION OF NAFLD FIBROSIS SCORE WITH USG
FATTY LIVER GRADING
                 Risk of Fibrosis
UsgAbd-Fatty Liver Grade Total
Pearson
Chi-
Square
VALUE
27.620
(a)
Df =4
P
VALUE
0.000
Grade I Grade II Grade III
Low Count 12 12 0 24
% within Risk
of Fibrosis 50.0% 50.0% .0% 100.0%
% within
UsgAbd-Fatty
Liver Grade
9.8% 7.4% .0% 7.5%
Intermediate Count 82 66 16 164
% within Risk
of Fibrosis 50.0% 40.2% 9.8% 100.0%
% within
UsgAbd-Fatty
Liver Grade
66.7% 40.5% 48.5% 51.4%
High Count 29 85 17 131
% within Risk
of Fibrosis 22.1% 64.9% 13.0% 100.0%
% within
UsgAbd-Fatty
Liver Grade
23.6% 52.1% 51.5% 41.1%
Total Count 123 163 33 319
% within Risk
of Fibrosis 38.6% 51.1% 10.3% 100.0%
% within
UsgAbd-Fatty
Liver Grade
100.0% 100.0% 100.0% 100.0%
By applying CHI Square test risk of fibrosis by NAFLD score
correlates with the degree of fatty liver by ultrasound.(P <0.001 highly
significant).
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DISCUSSION
The present study entitled ‘’CLINICAL PROFILE OF NON-
ALCOHOLIC FATTY LIVER DISEASE AND NONINVASIVE
ANALYSIS OF NAFLD FIBROSIS SCORE AMONG TYPE 2
DIABETIC PATIENTS IN A TERTIARY CARE HOSPITAL’’ was
done in government Stanley medical college and hospital is a prospective
study conducted in diabetic population attending diabetology outpatient
clinic from April 2013 to March 2014.
During this study 500 eligible patients were assessed for the
presence of fatty liver by ultrasound . 319 probable NAFLD patients were
identified based on the ultrasound and graded  on the scale of I-III
standardised on a semi quantitative scale of assessment of hepatic
involvement.
NAFLD is a new age epidemic and an alarming condition
progressing to end stage liver disease, pathologically  resembling
alcoholic liver injury. Clinical implications are obtained for NAFLD
mostly of  its common prevalance in general population and its
progression to cirrhosis and liver failure.
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From a lot of clinical and experimental data  NAFLD is considered
as hepatic expression of the metabolic syndrome. Urbanisation and
western life style including sedentary life and  high fat diet  which
adversely affect the risk factors associated with metabolic syndrome and
unmasks the genetic tendency  that exists in Indian population.[97]
The gold standard is liver biopsy for  the diagnosis of NAFLD.
several studies compared the diagnostic utility of ultrasound imaging
with liver biopsy and found a sensitivity of > 90% and specificity of >
80% [98].Patient  will not convince for liver biopsy because it is invasive
for a disease which is non-serious and mostly asymptomatic condition.
Diabetes is an additional risk for advanced NAFLD and patients
with T2DM  should be labelled as high risk group and  screened for
NASH .Very few studies from India on  NAFLD patients with diabetes
have correlated severity based on ultrasonogrpahy and studied the non
invasive methods to identify the risk for high grade fibrosis.
The NAFLD Fibrosis Score , BARD, AST to Platelet Ratio
Index(APRI), and FIB-4 are the more widely investigated non-invasive
tools to cross-sectionally predict advanced fibrosis in NAFLD[5]. The
NAFLD Score is based on six easily available parameters (Age, BMI,
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hyperglycaemia, platelet count, albumin, AST/ALT ratio) and  is
clinically useful to  identify NAFLD patients who have  higher likelihood
of  bridging ?brosis and/or cirrhosis.[6]
There is an urgent need for using these non invasive scores in our
population to identify advanced fibrosis in patients with NAFLD that
may decrease the number of patients  requiring liver biopsy to diagnose a
milder form of the disease.
          Since NAFLD is  more prevalent  among the diabetic patients than
the general population and very few data are available on  how to non
invasively analyse and grade the risk of fibrosis, this study will give
knowledge for planning an algorithmic approach based on the most
frequently associated factors in this part of the country. The present study
focuses on the ultrasound based screening for fatty liver and application
of a NAFLD fibrosis score to grade the level of fibrosis. Further this
predicted score is compared with fibroscan values of liver stiffness to
assess the performance of the score to identify advanced fibrosis so as to
apply in our population.
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Distribution of severity of fatty liver on ultrasound:
In this study, 63.8% of the diabetic patients had fatty liver
(NAFLD). Mohan et al reported the occurance of NAFLD in diabetics to
be 54.5%.
Roliagarwal reported that 48.1%, 40.3% and 11.3% had  grade I,
II and III fatty liver respectively.  This was comparable to the
observations made in this study, in which 38.5% of  them had grade I, 51
% had grade II and 10.3% had grade III fatty liver.
Age and sex:
        In this study the mean age was found to be 54.62±9.75 and 52.65
among the NAFLD and non NAFLD group respectively. The majority of
patients are in the age group of 56-65 years and 46-55 years in NAFLD
and non NAFLD group respectively. In other Indian studies mean age
was reported to be 42.90±10.54 years by Roli Agarwal et al,
40.9±11.1Years by Bajaj  et  al115, 37.84±10.71 by Ajay duseja et al.118
This difference of almost 10 years could be because our cases were from
those who reported to our hospital for various ailments and not from a
healthy subset of the population.
In this study majority are females i.e. 265 out of 319 (83.1%) in
NAFLD group and 144 out of 181(79.6%) in Non NAFLD group. In an
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Indian study by D Amarapurkar et al in which there was female
preponderance of 52.2%. Female preponderance could be because major
risk factors for the occurance and severity of NAFLD such as  central
obesity and diabetes are more in females. Western studies have also
reported a female predominance in NAFLD patients.[163-177]  Higher
incidence in men was found by Bacon et al from Missouri, USA. Few
studies have also reported an equal incidence in males and females like
Bajaj etal (49% females).
Clinical signs and symptoms:
In our study group 125/319 (39.18%) patients were asymptomatic.
Indian studies have reported 30.8 to 38% patients to be asymptomatic
which is similar to the present study. Western studies have reported 47.7
to 64% patients to be asymptomatic which is higher than our study.[103,105-
108]
In our study 194/319 (60.81%) patients had symptoms of liver
disease, right upper abdominal pain or discomfort (47.02%), Fatigue
(47.02%) and malaise (23.51%) were the dominant symptoms.
Amarapurkar et al[114] reported 69.23% symptomatic patients having
right hypochondriac pain as the presenting complaint.  In the study by
Agarwal et al 64% [119] patients were symptomatic and right upper
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quadrant pain, fatigue and malaise were the main symptoms.   Powell  et
al[105]reported 52.38% patients to be symptomatic having right upper
quadrant pain, lethargy and nausea as the presenting complaints.  In the
study by Bacon et al[106] 36% were symptomatic and had right upper
abdominal pain, malaise and fatigue.
Body mass index:
Mean BMI in our study was28.04+4.12 kg/m2and 24.44+3.08 in
NAFLD and non NAFLD group respectively. The mean BMI within the
NAFLD group was found as Grade-I :26.65 +3.4 , Grade-II :28.51+4.05,
Grade-III :30.92+4.96 respectively.
        This study shows higher mean BMI in the NAFLD patients when
compared with other Indian studies: D amarapurkar et al 26.6 ±5.1,
Bajaj et al 26.7±4.4 and 26.7 by Kaushal et al[116].  When patients were
classified by degree of obesity 46 out of 319(14.4%) of NAFLD patients
were overweight(BMI=23-24.9),147 out of 319 (46.08%) were
moderately obese (BMI=25-29.9) and 97 out of 319 (30.4%) patients
were severely obese (BMI>30).There was statistical significance
(P<0.001) when comparing the means of the BMI within the NAFLD
cases using ANOVA. Studies have described obesity occurring anywhere
from 60 to 100%.
65
DEMOGRAPHIC PROFILE OF CASES WITH NAFLD:
INTERNATIONAL STUDIES
Author (yr) Studydesign N
Obese
(%)
Diab
-etes
(%)
Trigly-
ceride
(%)
Female
(%)
Sympt-
omatic
(%)
Advanced
fibrosis
(%)
Hilden et
al.99(1973)
Series (r) 32 NA NA NA NA NA NA
Adler and
Schaffner100
(1979)
Case series
(r)
29 100 2 48 76 NA 47
Ludwig et
al.101(1980)
Case series
(r)
20 90 50 67 65 NA 15
Itoh et
al.102(1987)
Comparativ
ecase
series (r)
16 100 5 63 75 NA 19
Diehl et
al.103(1988)
Comparativ
ecase
series (r)
39 71 55 20 81 23 39
Lee 104
(1989)
Case series
(r)
49 69 51 NA 78 0 34
Powell et
al.105
(1990)
Case series
(r)
42 95 36 81 83 52 50
Bacon et
al.106(1994)
Case series
(r)
33 39 21 21 42 36 39
Teli et al.107
(1995)
Case series
(r)
40 30 10 23 45 20 NA
Pinto et
al.108 (1996)
Case series
(r)
32 34 34 28 75 6 55
Laurin et
al.109(1996)
CT (r) 40 70 28 NA 73 NA NA
George et
al.110 (1998)
Case series
(r)
151 NA NA NA 49 NA NA
Angulo et
al.111(1999)
Case series
(r)
60 28 NA 67 NA 27
Matteoni et
al.112(1999)
Case series
(r)
132 NA 22 NA 52 NA 15
Garcia-
Monzon et
al.113
(2000)
Case series
(r)
41 NA 15 15 65 NA 10
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ANTHROPOMETRIC AND BIOCHEMICAL DATA OF
PATIENTS  WITH  NAFLD INDIAN STUDIES
variable
Deepak
amar-
papurkar
et al114
S bajaj et
al115
Kaushal
madan et
al116
Deepauc
hil et al
a117
Ajay
duseja et
al118
Roliagraw
al
et al 119
Age 39.1±12.3 40.1±11.1
82.1%
51 37.84±10.
71
42.90±10.5
4
Sex(%) 47.8(M) 51(M) 46(M) 72(M) - 64.5(M)
BMI(kg/m2) 26.6±5.1 26.7±4.4 26.7
69.4%
28.58±4.2
5 20%(>24.
9)
Waist
circumference
(cm)
-
57.1%
89.2±13.9
58.9%
- 99.96±11.
04
47.1%-
ncep-
atpIII
42%(>90-
m: >80-f)
96.03±8.45
95%
Blood
pressure
(mmhg)
- 128.2±17.
4/
83.2±12.3
48.72%
11.8%
28.4% 10%(>130
/85)
-
-
Bilirubin - - 0.8 - - -
AST(IU/L) 19.2±4.5 - 66 37.41±14.
50
57.8±29.2 76.05±41.7
4
ALT(IU/L) 24.3±9.8 - 98 38.74±17.
96
76.3±27.9 100.31±43.
74
Alk
phosphatase
(IU/L)
- - 159 - - 203.20±5.8
7
Albumin
(gm%)
- - 47 - -
Total
Cholesterol
(mgm%)
- 176.4±40.
9
180 187.92±3
6.32 36%(>200
mgm%)
201.30±44.
49
Triglyceride
(mgm%)
- 136.4±68.
9
23.1%
145
40.8%
170.02±8
8.90
43.6%
53%(>150
mgm%)
177.9161.1
2
HDL
cholesterol
(mgm%)
- 42.6±8.7
66.7%
41
36.4%
46.61±9.4
8
29.3%
66%(<40-
f:<50-m)
45.0110.14
Metabolic
syndrome
- 41% 20.9% 47.1% 50% -
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BIOCHEMICAL PROFILE OF CASES WITH NAFLD:
LABORATORY VALUES- INTERNATIONAL STUDIES
Author (yr)
Study
design N
Mean
or
median
SAP
IU/L
Mean
or
median
AST
IU/L
Mean
or
median
ALT
IU/L
Mean
AST/
ALT
ratio
Mean
bilirubin
mg/dL
Mean
albumin
gm/dL
Hilden et
al.99(1973)
Series (r) 32 NA NA NA NA NA NA
Adler and
Schaffner100
(1979)
Case
series (r)
29 144 100 120 0.83 NA NA
Ludwig et
al.101(1980)
Case
series (r)
20 170 72 38 1.89 0.5 NA
Itoh et al.102
(1987)
Compara
tive case
series (r)
16 NA 114 137 0.83 NA NA
Diehl et
al.103(1988)
Compara
tive case
series (r)
39 NA NA NA NA NA Normal
Lee 104 (1989) Case
series (r)
49 103 89 104 0.85 0.7 4.2
Powell et
al.105(1990)
Case
series (r)
42 108 70 96 0.73 1.18 NA
Bacon et
al.106(1994)
Case
series (r)
33 139-
202
52-122 64-224 NA 1.5-2.3 NA
Teli et al.107
(1995)
Case
series (r)
40 157 NA 37 NA 0.2 NA
Pinto et al.108
(1996)
Case
series (r)
32 NA 60 91 0.35 0.7 3.4
Laurin et
al.109(1996)
CT (r) 40 234 vs
298
70 vs
88
113 vs
93
NA 0.7 vs0.6 NA
George et al.110
(1998)
Case
series (r)
151 NA 53 96 0.54 NA NA
Angulo et
al.111(1999)
Case
series (r)
206 63 82 0.88 0.7 4.3
Matteoni et
al.112(1999)
Case
series (r)
132 NA Normal 58 NA normal normal
Garcia-Monzon
et al.113
(2000)
Case
series (r)
41 190 NA 37 0.81 normal normal
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METABOLIC SYNDROME:
In this study, Metabolic syndrome (as per the NCEP ATP III
modified criteria using Asian Indian standards)was present in 73% of the
NAFLD patients and only 15.4% in non NAFLD patients. This
observation was much higher when compared with other Indian studies:
Ajayduseja et al (50%) and Deepa uchilet al (47.1%).
Among the NAFLD patients Grade I- 13%,  Grade II- 95.7%,
Grade III- 93.93% had metabolic syndrome. By applying CHI square test
P value was <0.001 highly significant.
LABORATORY PARAMETERS:
Liver function tests:
In this study, mean AST was found to be 32.72+12.964, mean ALT
was 23.81+12.722, mean albumin was 3.95+0.6542. If ALT <30 IU/l for
men and <19 IU/l for women (Prati et al) is considered as normal ranges
then elevation of serum transaminases was the most common
biochemical abnormality in our patients. AST and ALT levels were
elevated in 81.81% and 55.48 % of our patients respectively. Roli
Agrawal et al reported elevated ALT and AST in 97.6% and 98.4%
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respectively. Other studies have also reported a high incidence of raised
AST/ALT levels in patients ranging from 85-88%.When the means of
AST and ALT were compared in different grades of fatty liver, mean
AST  and ALT were not found to be statistically significant p value
>0.05. This could be explained because the study population were taken
from out patient department and most of them remained asymptomatic
for liver disease.
Mofrad et al[120] studied NAFLD in two groups of patients.  One
group comprised of 51 cases having normal ALT levels and the second
group comprised of 50 cases with raised ALT levels.  A greater
proportion of patients with normal ALT were asymptomatic compared to
those with higher ALT levels who were symptomatic (p<0.04), thus
further highlighting the fact that raised ALT levels are observed in
symptomatic patients.
ANALYSIS OF NAFLD FIBROSIS SCORE:
Total 319 ultrasound detected NAFLD patients were analysed with
the NAFLD fibrosis score in this study. Majority of the patients were
identified to have intermediate (164/319 = 51.41%) and high risk
(131/319 = 41.06%) of fibrosis. Most of the patients with Low score are
in the age group of 46-55yrs (50%), intermediate score are in the age
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group of 56-65 yrs(34.1%) and high score are in the age group of 56-65
yrs(38.9%).By applying CHI Square test P value <0.001 highly
significant implies higher the age, higher the NAFLD fibrosis risk score.
When compared the individual components of the NAFLD fibrosis
score within and between the various grades of the score (low,
intermediate, high) using ANOVA it is found that BMI, platelet count,
AST, albumin were statistically significant (P value <0.001).
In kakrani et al[121]study, the mean NAFLD ?brosis score with
grade 1 fatty liver was -0.44, grade 2 fatty liver was  -0.13, and grade 3
fatty liver was 0.15.
In our study the mean NAFLD ?brosis score with grade 1 fatty
liver was -0.0153, grade 2 fatty liver was 0.4562, and grade 3 fatty liver
was 0.5804.
COMPARISION OF NAFLD FIBROSIS SCORE WITH USG
FATTY LIVER GRADING
         In our study it is found that among the Grade I : 12/123
(9.7%),82/123 (66.6%),29/123(23.6%) had low, indeterminate and high
score respectively, among the Grade II : 12/163 (7.36%),66/163
(40.5%),85/163 (52.14%)had low, indeterminate and high score
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respectively, among the Grade III : 0(0%),16/33 (48.48%),17/33
(51.51%)had low, indeterminate and high score respectively.
By applying CHI Square test risk of fibrosis by NAFLD score
correlates with the severity of fatty liver by ultrasound.(P <0.001 highly
significant).Among the variables included in the score, BMI and albumin
were correlated significantly. These results conflict with the previous
study done by kakrani et al.[121]
In the study by kakrani et al, biochemical and imaging inpatients
with NAFLD who were overweight with BMI of  more than 25 were
correlated.106 patients participated in this study were assessed in terms
of  imaging evidence of  fatty liver, biochemical parameters, and NAFLD
?brosis score and BARD score.
 The imaging changes were compared with the non-invasive scores
of  NAFLD. They found that, Out of  two noninvasive scores, though
both statistically non signi?cant, NAFLD ?brosis score correlated better
with the imaging changes as compared to the BARD score. But this
relation was not found to be statistically signi?cant. They concluded that
imaging ?ndings of  fatty liver may not directly correlate with actual
?brosis in these patients.
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LIVER STIFFNESS  (LS) MEASUREMENT BY FIBROSCAN
(TRANSIENT ELASTOGRAPHY):
Measuring LS is a simple, non-invasive and efficient method to
identify individuals at high risk among NAFLD. In a study by Masura
baba et al[122] 60  out of 416(14.3%)  study participants had abnormal LS
value .LS significantly and positively correlated with Liver Function test
results and BMI. The LS was significantly higher among individuals with
fatty liver, than without.
In our study a total of 184 patients were selected based on the
grades of fatty liver by ultrasound (grade 2 and 3) who have intermediate
and high risk for fibrosis predicted by the NAFLD score. 84 patients did
not complete the fibroscan. Out of the 100 patients evaluated for the  liver
stiffness in our study,16%were in the category of <6 kPa, low risk for
fibrosis, 39% were in the category of 6-8 kPa , gray zone for fibrosis,
40% were in the category of  8-12.5 kPa,F-3 fibrosis  and 5%were in the
category of >12.5 kPa,F-4 fibrosis.
Most of them that is 33% and 34% were in the age group of 46-55
years and 56-65 years respectively.
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COMPARISION OF GRADES OF FATTY LIVER WITH GRADES
OF LIVER STIFFNESS (FIBROSCAN):
Of  the 100 patients,  67 patients and 33 patients were in grade II
and grade III respectively. Most of the patients 16 out of 33(48.48%) with
grade III fatty liver had LS in the range of 8-12.5 kPa and 28 out of 67
(41.79%) with grade II fatty liver had LS in the range of 6-8 kPa.
By applying CHI square test ultrasound grades of fatty liver do not
correlate with the fibroscan liver stiffness (P Value = 0.220).
COMPARISION OF NAFLD FIBROSIS SCORE AND
FIBROSCAN  LIVER STIFFNESS:
In this study, of the total 100 patients who underwent fibroscan
48% had intermediate and 52% had high risk based on the NAFLD
Score. Among the high risk 5 out of 52(9.61%) had LS >12.5 kPa (F4
fibrosis), 25 out of 52 (48.07%)had LS 8-12.5 kPa(F3 fibrosis).Among
the intermediate risk none had LS >12.5 kPa and 15 out of 48(31.25%)
had LS 8-12.5 kPa (F3 fibrosis).
By applying CHI Square test,  indeterminate and high risk score
correlate with  high liver stiffness value (P = 0.009).
39 out of 100 (39%) had LS of 6-8 kPa in the gray zone who may need a
liver biopsy to grade the degree of fibrosis whereas 61 out of 100 (61%)
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had LS value <6 or >8 kPa falls in either low or significant fibrosis
category hence liver biopsy can be avoided.
The NAFLD fibrosis score is a good non invasive predicting tool
since it is correlating with the different grades of fatty liver by ultrasound
and with the liver stiffness measurement by fibrosan. This observation
should be analysed and verified in future studies because no large
published series are available to support this finding.
Limitations:
The NAFLD score cannot accurately  estimate and differentiate
individual fibrosis stages and between histological evidence of
steatohepatitis or a simple steatosis unlike a liver biopsy. Blood tests used
in this score  are known to fluctuate with time and non-liver-related
conditions may change the blood indices(AST can be elevated even in
muscle injury). Another drawback is Selection bias towards patients with
high risk and more severe disease .The low risk with low grade fatty liver
patients were not subjected for Fibroscan so the estimation of the
sensitivity, specificity, positive predictive value, negative predictive
value of the NAFLD Score to exclude advanced fibrosis could not be
estimated. Low sample size because fibroscan could not be completed for
all screened subjects.
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CONCLUSIONS
The prevalence of non alcoholic liver disease among the diabetic
population in this study was  63.8%higher compared to other series.
Majority are females 83.1%  in contrast to other series and the
common age group was 56-65 years. The mean BMI was 28.04+4.12
kg/m2 and metabolic syndrome was present in 73%.
Among the  laboratory parameters used in the NAFLD fibrosis
score  raised AST more than ALT(Ratio >1),low serum albumin, low
platelet count, high BMI were statistically significant.
The non invasive NAFLD fibrosis score correlates significantly
with the different grades of fatty liver detected by ultrasound and also
with the liver stiffness measurement by transient elastography
(Fibroscan).
By comparing the intermediate and high NAFLD fibrosis score
with fibroscan liver stiffness, 61% had either low or significant fibrosis
and hence an invasive liver biopsy could be avoided in these set of
patients to grade the degree of fibrosis.
The combination of transient elastography (fibroscan) and
NAFLD fibrosis scoring system may provide better performance than
each of them used alone, in the non invasive analysis to select patients for
whom to do a liver biopsy  although this needs to be veri?ed in future
studies.
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CLINICAL PROFILE OF NON-ALCOHOLIC FATTY LIVER DISEASE AND
NONINVASIVE ANALYSIS OF NAFLD FIBROSIS SCORE AMONG TYPE 2
DIABETIC PATIENTS IN A TERTIARY CARE HOSPITAL
THESIS  PROFORMA
GUIDE: CANDIDATE:
General information
Name : Subject Id:
Age/sex :
Hospital No :
Address : Phone:
Occupation :
Literacy :
Per capita income:
Religion : Hindu/Muslim/Christian/Others
Diet :Veg/Non Veg/Mixed
Present history
S.NO SYMPTOMS PRESENT ABSENT DURATION
1 Abdominal pain
2 Abdominal Distention
3 Dyspepsia(ulcer/reflux/dysmotility)
4 UGI bleeding
5 Jaundice
6 Oedema legs
7 Cardiovascular
? chest pain
? dyspnoea on exertion
? guidiness
8 Diabetic Complications
? Retinopathy
? Nephropathy
? Neuropathy
9 Obesity complications
? joint pain
? constipation
? CVA
Past history
H/O DURATION DRUGS
T2DM OHA INSULIN
SHT
IHD
DYSLIPIDEMIA
CHRONIC LIVER DISEASE
TUBERCULOSIS
BRONCHIAL ASTHMA
MALIGNANCY
THYROID DISORDER
CHRONIC RENAL
DISEASE
Any other Drugs:
Steroids
Estrogen
Heparin
Valproic acid
Anti-viral
Parentral nutrition
H/O:
Jaundice
Abdominal Surgery
Blood Transfusion
Starvation
HBV
HCV
Family H/O:
Liver Disease
HBV
HCV
Diabetes
Hypertension
IHD
Personal H/O:
S.No H/O Present Absent Duration Amount
1 Smoking
2 Alcohol
3 I/V drug abuse
Appetite : Normal Lost
Bladder : Normal Abnormal
Bowel : Normal Abnormal
Sexual History : Significant  In-Significant
GENERAL EXAMINATION:
Anthropomerty
S.No Parameter Value Comment
1 Height (m)
2 Weight (kg)
3 BMI (kg/m2) >23
4
Waist Circumference (cm) Men > 90 cm
Women > 80 cm
Vital signs :
Pulse:      /min BP: mm of Hg
Pallor Icterus Cyanosis Clubbing Edema
JVP Lymphnodes  Hairs Skin
Peripheral Signs of liver cell failure if any ……………….............
Systemic Examination:
PA   : Tender Ascites Liver Spleen
CVS  : S1S2 Murmur
RS   :NVBS Added Sounds Effusion
CNS  :HMF Motor  Sensory Peripheral Neuropathy
/
INVESTIGATIONS:
S.NO INVESTIGATION VALUES
1. Hb
2. TLC
3. DLC
4. PLATELET
5. ESR
6. PT
7. INR
8. LFT-
? SR.BIL TOTAL/DIRECT
? SGOT/SGPT
? SAP/GGT
? T.PRO/ALB/GLB
9. BLOOD SUGAR
FBS/ PPBS/ RBS
10. BLOOD UREA
11. CREATININE
12. HBSAG
13. ANTI-HCV
14. URINE ANALYSIS
15. ASCITIC FLUID ANALYSIS
T.PRO/ALB/SUGAR
TLC/DLC
16. FASTING LIPIID PROFILE
? TOTAL CHOLESTEROL
? Sr.TGL
? LDL
? VLDL
? HDL
S.NO INVESTIGATION REPORT
1 E C G
2 USG ABDOMEN 1. Fatty Liver
a. Gr.1 (Mild Steatosis)
b. Gr.2 (Moderate Steatosis)
c. Gr.3 (Severe Steatosis)
2. Cirrhosis
3. Ascites
4. Spleenomegaly
3 PV DOPPLER
( OPTIONAL)
4 OGD SCOPY
( OPTIONAL)
5 CT SCAN ABDOMEN
( OPTIONAL)
6 MRI ABDOMEN
( OPTIONAL)
7 ANY OTHER ( OPTIONAL)
[LIVER BIOPSY / FIBROSCAN]
FORMULA:
NAFLD ?brosis score= -1.675 + 0.037 ×age (years) + 0.094 × BMI (kg/m2) + 1.13 ×
IFG/diabetes (yes=1, no= 0) +0.99 × AST/ALT ratio- 0.013 × platelet (×109/l) -0.66
×albumin (g/dl).
AGE  :
BMI :
IFG/diabetes (yes=1, no= 0):
AST/ALT ratio :
Platelet (×109/l) :
Albumin (g/dl) :
NAFLD ?brosis score=
<-1.455 Low Risk
-1.455 to 0.676 Intermediate
>0.676 High Risk
Metabolic Syndrome: Present Absent
FIBROSCAN LIVER STIFFNESS: <6kPa  /  6-8kPa  /  8-12.5kPa  /  >12.5kPa.
FINAL DIAGNOSIS:
GUIDE: INVESTIGATOR:
Consent  Form
I agree to participate in the study titled - “clinical profile of non-alcohoic fatty
liver disease and noninvasive analysis of NAFLD fibrosis score among type
2 diabetic patients in a tertiary care hospital”
I confirm that I have been told about this study in my mother tongue and have
had the opportunity to ask question.
I understand that my participation is voluntary and I may refuse to participate at
any time without giving any reason and without affecting my benefits.
I agree not to restrict the use of any data or results that arise from the study.
I agree to undergo the necessary investigation which is part of the study.
Name of the participant :
Signature / thumb impression :
Investigator :
S.NO H.NO NAME AGE SEX BP BMI WC HTG HDL MS PLT AST ALT Alb NFS RF USG FLS
1 69417 Kumar 37 M 0 19.4 0 0 0 0 320 21 11 4.4 N/A N/A 0 N/A
2 67386 Devadhathan 65 M 0 20.8 0 0 0 0 250 21 13 4.3 N/A N/A 0 N/A
3 95377 Malliga 60 F 0 24.3 0 0 0 0 270 28 19 4.4 N/A N/A 0 N/A
4 71570 Chitradevi 60 F 0 24.2 0 0 0 0 390 24 22 4.8 N/A N/A 0 N/A
5 83774 Ali 63 M 0 25.39 0 0 0 0 230 22 39 4.7 N/A N/A 0 N/A
6 98173 Shanthakumari 45 F 0 29.2 1 1 1 1 330 15 14 4.6 N/A N/A 0 N/A
7 83980 Annalakshmi 35 F 1 38.8 1 0 1 1 280 18 21 4.9 N/A N/A 0 N/A
8 98873 Saraswathi 50 F 0 25.1 0 0 0 0 250 29 39 4.9 N/A N/A 0 N/A
9 328 Vijayalakshmi 57 F 0 24.8 0 0 0 0 190 24 22 4.3 -0.333 I 1 N/A
10 48969 Malliga 57 F 0 24.7 0 0 0 0 270 23 24 4.6 -1.711 L 1 N/A
11 78402 Ali 47 M 0 19 0 0 0 0 260 19 17 4.7 N/A N/A 0 N/A
12 87032 Selvammal 53 F 0 29.3 1 1 1 1 300 15 17 4.6 -1.892 L 1 N/A
13 80114 Malarvizhli 41 F 0 29.9 1 1 1 1 300 18 26 4.9 N/A N/A 0 N/A
14 52067 Rani 44 F 1 35.1 1 0 1 1 300 33 66 4.8 N/A N/A 0 N/A
15 85655 Sivagami 57 F 1 30.66 1 0 0 0 350 24 34 4.7 N/A N/A 0 N/A
16 98856 Lakshmi 41 F 0 27.6 1 1 1 1 300 24 22 5 N/A N/A 0 N/A
17 75046 Logambal 38 F 0 23.5 0 0 0 0 170 22 26 4.8 N/A N/A 0 N/A
18 23256 Kanagavalli 54 F 0 26.6 1 1 0 1 320 16 19 4.8 -2.5 L 2 N/A
19 2090 Noorjahan 50 F 0 24.6 0 0 0 0 500 19 10 4.5 N/A N/A 0 N/A
20 101909 Guna 42 M 0 26.9 1 0 0 0 300 15 31 4.6 -2.5 L 1 N/A
21 90931 Kala 50 F 0 28.1 1 1 1 1 370 19 32 4.3 -2.5 L 2 N/A
22 50421 Abdul nazar 50 M 0 27.6 1 0 0 0 270 16 19 4.7 -1.879 L 1 N/A
23 73061 Lakshmi 65 F 0 21.2 0 0 0 0 370 13 20 4.8 -2.5 L 2 N/A
24 97301 Mani 55 M 0 21.6 0 0 0 0 110 18 15 4.5 N/A N/A 0 N/A
25 94593 Tahira 52 F 0 25.7 0 0 0 0 320 16 18 4.8 N/A N/A 0 N/A
26 72309 Meenatchi 29 F 0 18 0 0 0 0 190 10 19 4.4 N/A N/A 0 N/A
27 69063 Solaiyamma 45 F 0 28.9 1 1 1 1 320 17 15 4.3 -2.03 L 2 N/A
28 71958 Ashok kumar 44 M 0 23.8 0 0 0 0 260 21 19 4.5 N/A N/A 0 N/A
29 84419 Jothi 45 F 0 21.9 0 0 0 0 240 26 32 4.8 N/A N/A 0 N/A
30 83764 Rahimunisha 55 F 1 31.5 1 1 1 1 300 42 54 4.8 -1.847 L 1 N/A
31 5117 Kuppamma 55 F 1 34.1 1 1 1 1 260 18 13 4.6 -0.35 I 2 ND
32 92840 Usharani 52 F 1 35.4 1 1 1 1 180 20 17 4.8 0.363 I 2 8.8
33 37213 Krishnaveni 55 F 0 28.8 1 1 1 1 220 24 22 4.2 0.355 I 1 N/A
34 75194 Josemin 65 F 1 30.1 1 1 1 1 240 48 58 4.6 -0.647 I 2 ND
35 94472 Kothainayagi 59 F 0 24 0 0 0 0 340 17 20 4.5 -2.5 L 1 N/A
36 74622 Radha 40 F 0 24.4 0 0 0 0 350 40 79 4.3 N/A N/A 0 N/A
37 79360 Ellammal 58 F 0 29.3 1 1 1 1 390 24 23 4.8 -2.5 L 2 N/A
38 5533 Vasantha 62 F 0 21.1 0 0 0 0 390 20 15 4.6 N/A N/A 0 N/A
39 26074 Krishnaveni 50 F 0 28.7 1 1 1 1 320 18 22 4.2 -2.119 L 1 N/A
40 88687 Prema 55 F 0 23.6 0 0 0 0 350 17 16 4 N/A N/A 0 N/A
41 869/13 Ramesh 35 M 0 27.9 1 0 0 0 157 42 72 4.7 -1.193 I 1 N/A
42 50588 Nagabooshnam 60 F 1 33.3 1 1 1 1 400 34 15 5.1 -1.517 L 2 N/A
43 71457 Sairabanu 52 F 0 23.5 0 0 0 0 280 27 30 5 N/A N/A 0 N/A
44 94592 Komalam 52 F 0 22.7 0 0 0 0 240 64 52 5 N/A N/A 0 N/A
45 2860 Umawathi 53 F 1 36.1 1 1 1 1 370 35 24 4.9 -1.791 L 2 N/A
46 91722 Ramaiah 65 M 0 25.4 0 0 0 0 230 27 19 3.9 0.09 I 1 N/A
47 81260 Raju 56 M 0 28.7 1 1 0 1 250 23 21 3.4 -0.185 I 1 N/A
48 81856 Nirmala 45 F 1 38.7 1 1 1 1 350 21 27 3.2 -1.134 I 3 12.3
49 85927 Rejina 46 F 0 26.9 1 1 0 1 240 28 21 3.6 -0.49 I 2 ND
50 66605 Kokila 52 F 1 30.2 1 1 1 1 360 29 24 4.2 -2.038 L 2 N/A
51 73871 Malliga 48 F 0 22.9 0 0 0 0 270 31 28 4.6 N/A N/A 0 N/A
52 98176 Kasturi 49 F 0 20.1 0 0 0 0 340 18 19 3.8 N/A N/A 0 N/A
53 40683 Saroja 50 F 0 23.1 0 0 0 0 370 25 21 4.1 N/A N/A 0 N/A
54 102326 Lakshmi 50 F 1 40.5 1 1 1 1 280 23 25 3.8 -0.125 I 3 9.1
55 2361 Kasturi 55 F 0 21.6 0 0 0 0 260 25 23 3.6 N/A N/A 0 N/A
56 4617 Gunaselvi 46 F 0 27.1 1 0 1 1 70 21 18 4.6 0.913 H 1 N/A
57 6821/07 Meena 64 F 0 23.5 0 0 0 0 160 30 18 5.2 0.17 I 1 N/A
58 2684 Ramasamy 50 M 1 33.3 1 1 1 1 230 22 18 4.3 -0.183 I 2 9.1
59 1226 Rukmani 67 F 0 26.9 1 0 0 0 100 31 27 4.2 N/A N/A 0 N/A
60 2655 Sivagami 38 F 0 24.97 0 0 0 0 140 57 69 3 0.226 I 1 N/A
61 34901 Chellam 52 F 1 36.36 1 1 1 1 210 30 18 4.4 0.813 H 1 N/A
62 12698 Vijaya 48 F 0 19.84 1 0 0 0 180 22 19 4.6 -1.134 L 1 N/A
63 38816 Muthumani 56 F 1 38.57 1 1 1 1 200 22 18 4 1.123 H 2 9.1
64 36190 Kunjara 60 F 0 23.37 1 0 0 0 180 35 21 4.1 N/A N/A 0 N/A
65 2445 Madhiyalagan 49 M 0 26.26 1 1 0 1 280 23 18 4.6 -1.675 L 2 N/A
66 7643 Isabel 37 F 0 24.89 1 0 0 0 300 21 18 4.2 N/A N/A 0 N/A
67 13664 Mala 50 F 1 32.27 1 1 1 1 250 40 28 2.4 0.919 H 3 6.8
68 21445 Nayagam 60 F 0 25.97 1 0 0 0 260 31 19 4.4 N/A N/A 0 N/A
69 2436 Lakshmi 52 F 0 21.36 1 0 0 0 160 21 15 3.9 N/A N/A 0 N/A
70 1837 Sarada 50 F 0 23.78 1 0 0 0 250 31 22 4.6 N/A N/A 0 N/A
71 7250 Kathija 40 F 0 26.3 1 0 0 0 300 24 15 3.8 N/A N/A 0 N/A
72 5465 Ponnamma 52 F 0 26.67 1 0 0 0 250 31 22 5.7 -1.731 L 1 N/A
73 6693 Radhakrishnan 72 M 0 26.08 1 1 0 1 150 32 25 3.9 1.314 H 2 ND
74 2178 Kalavathi 45 F 0 23.07 1 1 0 1 260 28 17 3.7 -0.903 I 2 ND
S.NO H.NO NAME AGE SEX BP BMI WC HTG HDL MS PLT AST ALT Alb NFS RF USG FLS
75 1124 Vasantha 49 F 0 22.83 1 0 0 0 190 28 31 4.4 N/A N/A 0 N/A
76 3478 Sampoornam 60 F 0 26.35 1 1 0 1 100 28 15 5.2 1.268 H 2 8.8
77 17765 Chandra 53 F 0 24.46 1 0 0 0 210 31 15 4.6 -0.005 I 1 N/A
78 14465 Susila 65 F 0 24.44 1 0 0 0 120 28 17 5.2 0.796 H 1 N/A
79 92302 Ponnammal 70 F 0 22.35 1 0 0 0 260 63 45 3.4 N/A N/A 0 N/A
80 4452 Muniyamma 68 F 0 23.11 1 0 0 0 140 24 18 4.5 N/A N/A 0 N/A
81 7296 Alli 45 F 0 26.64 1 0 0 0 180 21 28 3.5 -0.283 I 1 N/A
82 63446 Dinakaran 32 M 0 29.62 1 1 1 1 160 18 15 3.9 -0.043 I 3 10.2
83 68426 Malligeshwari 56 F 1 34.96 1 1 1 1 180 21 25 3.1 1.259 H 3 12.7
84 73244 Kumar 28 M 0 22.04 0 0 0 0 200 18 15 4.4 -1.753 L 2 N/A
85 92028 Kanniyappan 55 M 0 27.06 1 1 1 1 190 24 32 3.6 N/A N/A 0 N/A
86 203814 Lakshmi 70 F 0 20.41 0 0 0 0 160 14 18 4.5 N/A N/A 0 N/A
87 7784 Peter 40 M 0 25.71 1 0 0 0 120 26 21 3.7 0.575 I 1 N/A
88 67600 Pangujam 55 F 0 25.71 1 0 0 0 200 25 29 4.8 -1.008 I 1 N/A
89 293244 Lakshmi 51 F 0 26.84 1 0 0 0 140 19 16 3.5 N/A N/A 0 N/A
90 41223 Selvi 52 F 0 18.97 0 0 0 0 210 24 21 4.5 N/A N/A 0 N/A
91 68343 Satyanarayana 72 M 0 22.68 1 0 0 0 180 21 20 3.8 N/A N/A 0 N/A
92 68342 shyamalabai 66 F 0 29.96 1 1 1 1 220 42 34 4.4 N/A N/A 0 N/A
93 99662 Sulekabeevi 63 F 0 24.84 1 0 0 0 240 38 29 4 -0.342 I 1 N/A
94 71198 Joycee 55 F 0 26.16 1 1 0 1 160 25 19 3 1.192 H 2 ND
95 63737 Manna 70 F 0 19.02 1 0 0 0 260 21 29 3.2 N/A N/A 0 N/A
96 87108 Saathayee 65 F 0 28.06 1 1 1 1 250 20 25 3.8 -0.468 I 3 8.6
97 102128 Prema 55 F 0 25.39 1 0 0 0 150 22 19 4.2 0.301 I 1 N/A
98 1776 Sheela 48 F 1 33.33 1 1 1 1 240 18 15 3.4 0.188 I 2 7.5
99 68460 Zaithoonbeevi 54 F 1 32.44 1 1 1 1 180 19 15 3.8 0.908 H 2 ND
100 3498 Umadevi 47 F 0 23.5 1 0 0 0 180 29 25 3.8 N/A N/A 0 N/A
101 94592 Komala 55 F 0 23.31 1 0 0 0 180 18 15 4.4 N/A N/A 0 N/A
102 73213 Ramjaanbeevi 66 F 1 32.89 1 1 1 1 300 29 19 3.5 0.29 I 1 N/A
103 96480 Palani 48 M 0 22.38 0 0 0 0 400 49 18 3.7 N/A N/A 0 N/A
104 3342 Manniyamma 61 F 0 28.94 0 0 1 0 240 43 32 4.6 -0.393 I 1 N/A
105 77580 Gandhimathi 65 F 0 27.06 1 1 1 1 180 38 25 3.8 N/A N/A 0 N/A
106 2035 Alagamma 65 F 0 28.76 1 1 1 1 200 37 29 4.6 0.191 I 3 11.7
107 96318 Nagarathinam 52 F 0 24 0 0 0 0 200 39 26 3.2 0.408 I 3 10.4
108 74286 Andal 65 F 0 27.06 1 1 0 1 160 49 30 4.5 0.971 H 3 6.3
109 501823 Nagammal 50 F 0 25.81 1 0 0 0 220 28 20 3.6 N/A N/A 0 N/A
110 93955 Vimala 55 F 0 25.68 1 0 0 0 160 32 28 4.1 0.249 I 1 N/A
111 103606 Mehabulbeevi 55 F 0 27.39 1 0 1 1 190 19 16 3.4 0.526 I 1 N/A
112 89393 Vijayalakshmi 65 F 0 23.78 0 0 0 0 200 22 17 4.5 -0.194 I 2 ND
113 103795 Alamelu 50 F 0 26.95 1 1 0 1 180 28 26 4.5 -0.406 I 3 8.7
114 6875 Sathya 60 F 0 24.73 1 0 0 0 190 39 26 3.5 N/A N/A 0 N/A
115 91602 Kasturi 53 F 0 19.91 0 0 0 0 260 32 24 4.5 -0.1742 L 1 N/A
116 82176 Gracy 65 F 0 25.21 1 0 0 0 200 38 28 3.7 0.531 I 1 N/A
117 5770 Zahidabeevi 52 F 1 36.74 1 1 1 1 180 26 22 3.9 1.089 H 2 10.7
118 51005 Subatra 67 F 0 22.37 1 1 0 1 200 42 29 3.8 0.363 I 2 6.3
119 3117 Susila 61 F 0 28.54 1 1 1 1 220 21 19 4.8 N/A N/A 0 N/A
120 64221 Rajakumari 60 F 0 28.13 1 1 1 1 200 29 19 4 N/A N/A 0 N/A
121 74306 Yamuna 48 F 0 29.67 1 1 1 1 180 34 2 3.9 0.401 I 2 6.8
122 103245 Ravichandran 50 M 0 25.77 1 1 1 1 240 26 22 3.5 -0.533 I 2 ND
123 6861 Thomas 48 M 0 19.1 0 0 0 0 260 29 19 4.6 N/A N/A 0 N/A
124 1880 Dhanalakshmi 32 F 1 32.37 1 1 1 1 280 30 24 3 -0.701 I 2 7.8
125 98653 Deivarani 46 F 0 22.6 1 0 0 0 190 36 24 4.2 -0.476 I 1 N/A
126 71640 Navamani 55 F 0 25.1 1 0 0 0 260 40 25 3.5 N/A N/A 0 N/A
127 3766 Babyvasanthi 52 F 1 31.63 1 1 1 1 120 46 35 3.6 1.717 H 2 11.3
128 89533 Baby 70 F 0 26.3 1 1 0 1 120 35 28 4.6 1.159 H 2 ND
129 64443 Dhanalakshmi 45 F 0 20.54 0 0 0 0 140 46 23 3.2 1.099 H 1 N/A
130 3530 Tamilselvi 42 F 1 34.72 1 0 1 1 120 33 26 4.5 N/A N/A 0 N/A
131 3298 Prema 61 F 0 25.97 1 0 0 0 150 39 24 3.2 1.7 H 1 N/A
132 66723 Santoshiyammal 45 F 0 26.16 1 0 0 0 120 24 22 3.8 N/A N/A 0 N/A
133 72068 Senbagavalli 57 F 0 29.55 1 1 1 1 130 29 26 4.8 0.588 I 1 N/A
134 38735 Rukmani 53 F 0 22.22 0 0 0 0 180 35 28 4.8 N/A N/A 0 N/A
135 40720 Rani 53 F 0 17.86 0 0 0 0 180 32 25 3.1 N/A N/A 0 N/A
136 3990 Muthamma 65 F 0 26.16 1 0 0 0 140 26 22 3.7 N/A N/A 0 N/A
137 5858 Kanniyammal 48 F 1 30.3 1 1 1 1 160 48 26 3.4 1.583 H 2 9.1
138 103134 Velsamy 52 M 0 27.64 1 1 1 1 220 28 24 3.4 N/A N/A 0 N/A
139 90337 Saroja 45 F 0 27.7 1 1 0 1 120 34 22 4.5 0.724 H 2 12.8
140 69825 Samuelantony 72 M 0 21.99 1 0 0 0 130 35 26 3.4 1.585 H 1 N/A
141 55556 Manoharan 43 M 0 23.88 1 1 0 1 150 45 38 4.1 -0.193 I 2 5.4
142 89289 Rangasamy 67 M 0 28.25 1 1 1 1 160 21 19 4.1 0.898 H 2 ND
143 54426 Mehaboobeevi 55 F 1 30.41 1 1 1 1 120 62 40 3.9 1.749 H 2 11.7
144 7152 Murugammal 63 F 0 28.04 1 1 1 1 130 58 26 4.6 1.904 H 1 N/A
145 186 Baby 60 F 0 26.25 1 0 0 0 140 81 67 5.9 -0.375 I 1 N/A
146 80938 Jegadeeshwari 50 F 1 33.29 1 1 1 1 140 26 22 4.5 0.814 H 2 9.5
147 85836 Muthulakshmi 57 F 0 27.03 1 1 0 1 130 30 29 4.5 0.469 I 2 7.5
148 950 Revathy 51 F 0 23.81 0 0 0 0 130 58 32 3.5 N/A N/A 0 N/A
S.NO H.NO NAME AGE SEX BP BMI WC HTG HDL MS PLT AST ALT Alb NFS RF USG FLS
149 4900 Selvi 32 F 0 25.57 1 1 0 1 140 62 45 3.5 0.277 I 3 5.8
150 66979 Amsaveni 65 F 1 31.83 1 0 0 0 120 38 24 3.9 N/A N/A 0 N/A
151 102622 Tamaraiselvi 47 F 0 24.2 0 0 0 0 200 21 17 4 -0.548 I 2 5.3
152 41641 Susila 53 F 0 26.84 1 0 0 0 300 38 20 4 -0.72 I 1 N/A
153 2412 Jothi 42 F 1 30.43 1 1 1 1 260 31 23 3.3 -0.354 I 2 ND
154 64192 Shivaleela 68 F 0 23.19 0 0 0 0 200 19 16 4.2 -0.046 I 1 N/A
155 3507 Ravichandran 41 M 0 21.77 0 0 0 0 160 18 13 2.9 0.395 I 1 N/A
156 5600 Madhavan 40 M 0 22.6 0 0 0 0 180 31 22 3.5 -0.196 I 1 N/A
157 85855 Joharabeevi 72 F 1 31.01 1 1 1 1 200 41 32 3.8 1.194 H 2 ND
158 1816 Durga 26 F 0 28.93 1 1 1 1 160 27 16 4.4 -0.177 I 1 N/A
159 91374 Manickam 62 M 0 21.45 0 0 0 0 210 46 31 3.7 0.062 I 2 4.2
160 104526 Pushpa 31 F 0 28.04 1 1 1 1 160 22 15 3.3 0.432 I 1 N/A
161 93985 Sahul hameed 55 M 1 31.64 1 1 1 1 210 16 22 3 0.474 I 2 4.5
162 200922 Saradamma 70 F 0 25.21 1 1 0 1 210 26 17 3.4 0.955 H 2 ND
163 3932 Jeevarathinam 70 F 0 20.4 1 0 0 0 240 23 18 3.7 N/A N/A 0 N/A
164 84550 Jamunabegam 63 F 0 26.99 1 1 0 1 200 35 26 4.2 0.284 I 2 5.4
165 27513 Subramani 63 M 0 21.72 0 0 0 0 100 15 17 3.6 1.025 H 1 N/A
166 3841 Kamala 49 F 0 27.59 1 1 1 1 280 19 16 3.4 N/A N/A 0 N/A
167 95293 Meenatchi 50 F 0 27.89 1 0 1 1 180 21 16 3.3 0.708 H 1 N/A
168 8081 Jamuna 38 F 0 25.45 1 0 0 0 250 25 19 3.7 N/A N/A 0 N/A
169 21527 Shanmugathai 58 F 0 25.44 1 0 0 0 240 22 17 3.5 -0.156 I 1 N/A
170 103411 Indrani 40 F 1 43.35 1 1 1 1 160 38 29 4 1.587 H 2 8.1
171 2244 Ramayeeamma 70 F 0 26.16 1 0 0 0 210 22 17 3.8 N/A N/A 0 N/A
172 91468 Lilly 50 F 0 28.76 1 1 1 1 200 33 16 4.7 0.348 I 1 N/A
173 68579 Mumtajbegam 30 F 0 24.67 0 0 0 0 250 25 18 3.6 N/A N/A 0 N/A
174 3301 Karpagam 44 F 1 35.21 1 1 1 1 210 19 17 2.9 0.855 H 3 13.8
175 82684 Bhavani 46 F 1 35.67 1 1 1 1 180 25 17 3.3 1.448 H 2 10.7
176 2976 Kanagalakshmi 40 F 1 43.11 1 1 1 1 250 51 32 4.1 0.609 I 2 6.3
177 6023 Rani 43 F 0 26.16 1 0 0 0 200 32 19 4 N/A N/A 0 N/A
178 53244 Sankaramma 60 F 0 26.4 1 0 0 0 200 45 26 4.1 0.564 I 1 N/A
179 99321 Madhivanan 44 M 0 26.03 0 0 0 0 250 45 30 4.2 -1.007 I 1 N/A
180 6681 Alagiyaperumal 74 M 0 27.99 0 0 0 0 190 59 32 4.8 1.011 H 1 N/A
181 5537 Ponnamma 57 F 0 22.68 0 0 0 0 280 36 15 4.1 N/A N/A 0 N/A
182 6361 Shanthi 45 F 0 29.48 1 1 1 1 280 52 30 4.6 -1.069 I 1 N/A
183 6362 Shanmugam 62 M 0 25.04 1 0 0 0 250 48 31 4.9 N/A N/A 0 N/A
184 2911 Vasantha 53 F 0 28.19 1 1 1 1 200 28 32 3.9 N/A N/A 0 N/A
185 32781 Gajalakshmi 59 F 1 31.11 1 1 1 1 160 46 21 4 2 H 2 12.3
186 14980 Dhanam 53 F 0 18.73 0 0 0 0 210 32 24 3.8 N/A N/A 0 N/A
187 3968 Panjali 53 F 1 32.89 1 1 1 1 120 46 21 4 2 H 2 9.3
188 23980 Prema 50 F 0 28.72 1 1 1 1 250 32 19 3.6 N/A N/A 0 N/A
189 45876 Pichumani 65 F 0 27.34 1 0 1 1 180 52 30 3.1 1.76 H 1 N/A
190 52178 Yasodha 50 F 0 27.03 1 1 0 1 180 48 31 4 0.399 I 2 7.4
191 66415 Nagamma 70 F 0 24.97 1 1 0 1 190 62 30 3.9 1.394 H 2 5
192 38021 Mohana 65 F 0 26.9 1 1 0 1 120 41 30 3.5 1.872 H 2 ND
193 4587 Ansari 37 M 0 27.92 1 0 0 0 200 32 24 3.3 -0.01 I 1 N/A
194 81754 Fathima 44 F 1 31.39 1 1 1 1 150 46 30 3.2 1.49 H 2 8.6
195 72608 Susila 55 F 0 22.68 0 0 0 0 160 32 21 3 1.07 H 1 N/A
196 70281 Rahima 47 F 1 30.96 1 1 1 1 200 42 26 3.1 1.057 H 2 5.3
197 86331 Lakshmi 53 F 0 28.13 1 1 1 1 210 39 22 3.6 0.709 H 2 ND
198 587 Zelumbeevi 64 F 1 33.76 1 1 1 1 180 46 30 3 2 H 3 6.7
199 74900 Malathi 48 F 0 28.15 1 1 1 1 210 45 31 4.1 -0.122 I 2 6.8
200 71863 Seniyamma 45 F 0 27.66 1 1 0 1 180 32 15 3.1 1.416 H 2 7.7
201 68765 Sulochana 50 F 0 23.07 1 0 0 0 280 41 22 3.3 N/A N/A 0 N/A
202 232 Rashidhabegum 55 F 0 23.5 1 0 0 0 180 41 28 3.2 0.697 H 1 N/A
203 1019 Kajamoideen 50 M 0 29.39 1 1 1 1 120 25 15 4.8 N/A N/A 0 N/A
204 92376 Jamuna 55 F 0 29.15 1 1 1 1 200 22 20 4.6 -0.317 I 1 N/A
205 62413 Devi 53 F 1 31.22 1 1 1 1 180 34 26 4.7 0.203 I 3 9.2
206 6939 Mythili 58 F 0 21.45 1 0 0 0 160 49 70 5.1 N/A N/A 0 N/A
207 89434 Vasanthi 44 F 0 26.04 1 1 0 1 160 49 41 5 -0.666 I 2 ND
208 91640 Roopavathy 60 F 0 26.67 1 0 0 0 260 24 13 4.7 -0.472 I 1 N/A
209 3903 Thangam 65 F 0 29.52 1 1 1 1 160 25 18 4.1 1.224 H 2 ND
210 81785 Selvamary 41 F 0 29.14 1 1 1 1 160 25 15 3.9 0.707 H 2 ND
211 3617 Lakshmi 55 F 0 23.11 1 0 0 0 180 18 18 4.5 N/A N/A 0 N/A
212 3279 Paramasivam 59 M 0 16.65 0 0 0 0 200 26 11 5 N/A N/A 0 N/A
213 90975 Mangalakshmi 60 F 0 25.3 1 1 0 1 160 48 18 4.1 1.907 H 2 ND
214 70569 Subramani 58 M 0 28.6 1 1 1 1 150 31 26 5.2 0.088 I 2 7.8
215 272 Chandra 38 F 0 20.69 0 0 0 0 180 24 9 4.9 N/A N/A 0 N/A
216 6709 Thangakani 65 F 0 23.31 1 0 0 0 200 44 41 5.1 -0.852 I 1 N/A
217 74806 Devaraj 58 M 1 30.86 1 1 0 1 220 29 25 4.8 -0.378 I 1 N/A
218 8069 Gurusamy 75 M 0 23.38 1 1 0 1 200 30 10 4.3 1.96 H 2 ND
219 52437 Thilagavathy 62 F 1 31.39 1 1 1 1 160 34 24 4.6 0.986 H 2 ND
220 94977 Thomas 74 M 0 26.71 1 1 0 1 160 33 15 4.6 1.766 H 2 ND
221 104937 Fathima 50 F 1 31.62 1 1 1 1 160 110 176 4.5 -0.154 I 2 ND
222 6719 Kovilpillai 64 F 1 32.41 1 1 1 1 215 36 44 4.5 -0.085 I 1 N/A
S.NO H.NO NAME AGE SEX BP BMI WC HTG HDL MS PLT AST ALT Alb NFS RF USG FLS
223 74033 Shanthi 47 F 1 34.24 1 1 1 1 300 31 20 4.8 -1.121 I 3 6.9
224 6145 Vatchala 53 F 0 25.92 1 0 0 0 160 62 52 5.1 -0.413 I 1 N/A
225 99450 Vimala 45 F 1 36.74 1 1 1 1 200 47 36 4.7 0.164 I 1 N/A
226 61088 Selvi 48 F 0 28.89 1 1 1 1 170 43 20 3.6 N/A N/A 0 N/A
227 25978 Sundaraj 63 M 0 23.94 1 1 0 1 115 25 22 5.2 0.234 I 2 9.3
228 53889 Vasantha 57 F 1 31.04 1 1 1 1 160 23 9 4.6 1.896 H 2 ND
229 66821 Puspha 54 F 0 26.84 1 1 0 1 200 42 15 5.1 0.782 H 2 12.3
230 98051 Murugesan 43 M 0 22.59 1 0 0 0 300 29 18 4.8 N/A N/A 0 N/A
231 64991 Amsa 55 F 0 26.14 1 1 0 1 120 35 17 4.7 1.323 H 2 8.6
232 49025 Noorjahan 67 F 0 27.63 1 0 1 1 140 55 21 5.2 1.872 H 1 N/A
233 92646 Najmulbeevi 50 F 0 26.17 1 0 0 0 160 26 16 5.4 N/A N/A 0 N/A
234 42255 Jagadeesan 50 M 1 30.45 1 1 1 1 200 25 19 4.7 -0.232 I 2 ND
235 10816 Suriyakumari 65 F 0 25.78 0 0 0 0 200 76 23 5.5 N/A N/A 0 N/A
236 102500 Suguna 35 F 0 26.67 1 0 0 0 240 18 37 5.2 -2.5 L 1 N/A
237 1118 Devaki 43 F 1 33.29 1 0 1 1 320 19 16 4.5 N/A N/A 0 N/A
238 1516 Ellammal 63 F 0 28 1 1 1 1 240 27 13 4.8 N/A N/A 0 N/A
239 15438 Kamala 64 F 0 25.78 1 0 0 0 260 25 14 4.7 -0.468 I 1 N/A
240 16790 Malliga 60 F 0 26.53 0 0 0 0 300 29 15 5.3 -1.315 I 1 N/A
241 1389 Saritha 34 F 0 24.78 1 1 0 1 260 17 15 4.8 -2.384 L 2 N/A
242 81507 Rajeshwari 48 F 1 31.12 1 0 0 0 320 22 15 4.7 N/A N/A 0 N/A
243 67115 Chinrajpillai 71 M 0 26.16 1 0 0 0 180 33 16 4.8 N/A N/A 0 N/A
244 51151 Vellachi 60 F 0 27.27 1 1 1 1 260 31 16 4.4 N/A N/A 0 N/A
245 5762 Muniyamma 60 F 0 26.02 0 0 0 0 180 48 19 4.6 1.246 H 3 13.8
246 68723 Rohini 47 F 0 27.89 1 1 0 1 120 27 12 4.9 1.249 H 2 ND
247 21034 Saroja 43 F 0 28.13 1 1 1 1 200 17 9 4.7 -0.142 I 1 N/A
248 70809 Chinnaraj 47 M 0 29.43 0 1 1 0 230 29 13 4.9 N/A N/A 0 N/A
249 3801 Nageshwaran 55 M 0 27.61 0 0 0 0 130 55 23 5.2 1.331 H 1 N/A
250 100609 Vasantha 50 F 0 28.53 1 1 1 1 240 33 18 5.1 N/A N/A 0 N/A
251 9414 Lakshmi 60 F 0 29.76 1 1 1 1 200 25 16 5.1 N/A N/A 0 N/A
252 100584 Umarani 60 F 0 26.63 1 0 0 0 180 22 15 4.6 0.254 I 1 N/A
253 76210 Shanthi 45 F 0 27.56 1 0 1 1 200 27 15 5 -0.407 I 1 N/A
254 1073 Govindasamy 66 M 1 32.27 1 1 1 1 200 43 18 4.7 1.593 H 2 ND
255 79136 Mariyammal 65 F 0 27.68 1 1 0 1 250 33 15 3.8 0.882 H 2 ND
256 25268 Parasakthi 43 F 1 31.11 1 1 1 1 210 55 22 4.4 0.811 H 2 6.8
257 50099 Kasiammal 65 F 0 22.67 1 0 0 0 260 38 17 4.7 -0.278 I 1 N/A
258 73161 Umavathy 54 F 0 22.83 1 0 0 0 240 63 41 4.8 N/A N/A 0 N/A
259 71192 Fathimabeevi 55 F 0 25.15 1 0 0 0 190 51 37 4 0.109 I 1 N/A
260 93885 Badrunisha 45 F 1 40.57 1 1 1 1 200 30 19 3.6 1.521 H 3 12.3
261 2963 Mariambeevi 45 F 0 26.67 1 0 0 0 220 25 11 4.4 N/A N/A 0 N/A
262 68686 Indrani 49 F 0 29.67 1 1 1 1 210 37 22 3.1 N/A N/A 0 N/A
263 42244 Neelavathi 47 F 1 30.13 1 1 1 1 120 68 35 5.1 1.024 H 2 ND
264 2404 Muthulakshmi 61 F 1 31.22 1 1 1 1 210 31 26 4.5 0.127 I 3 8.1
265 621 Saradammal 70 F 0 19.29 1 0 0 0 200 25 17 4.1 N/A N/A 0 N/A
266 3867 Umerabaanu 47 F 0 22.58 1 1 0 1 190 83 51 4 -0.182 I 2 4.5
267 104077 Padmini 58 F 0 25.11 1 0 0 0 140 22 16 3.7 1.061 H 1 N/A
268 7397 Sudha 45 F 0 25.4 1 1 0 1 210 22 16 3.8 -0.369 I 2 ND
269 93209 Sundari 65 F 0 19.98 1 0 0 0 210 21 15 3.7 N/A N/A 0 N/A
270 3014 Fathimabeevi 65 F 0 26.52 1 1 0 1 190 29 16 4.3 0.839 H 2 ND
271 6757 Deivasundari 33 F 1 30.41 1 1 1 1 200 35 21 4.2 -0.187 I 3 7.4
272 97233 Shanthi 42 F 0 26.06 1 0 0 0 210 42 29 3.9 N/A N/A 0 N/A
273 53298 Ramani 42 F 1 32.03 1 1 1 1 190 25 15 3.4 0.956 H 2 ND
274 3417 Devakanni 61 F 1 30.33 1 1 1 1 210 55 19 4 2 H 2 ND
275 75872 Ramjaanbeevi 45 F 0 24.11 1 0 0 0 180 18 12 4.5 N/A N/A 0 N/A
276 24314 Balamma 47 F 0 22.31 1 0 0 0 220 38 17 3.9 N/A N/A 0 N/A
277 77858 Parvathy 50 F 0 25.4 1 0 0 0 160 21 15 3.6 N/A N/A 0 N/A
278 32518 Sundari 60 F 1 31.39 1 0 0 0 190 29 18 4.3 N/A N/A 0 N/A
279 83998 Murugan 39 M 0 21.93 1 0 0 0 200 46 21 4.1 N/A N/A 0 N/A
280 73218 Narasaiah 63 M 0 25.08 1 1 0 1 160 32 15 4 1.536 H 2 ND
281 39556 Lakshmiammal 45 F 1 30.25 1 1 1 1 180 41 30 3.9 0.402 I 2 7.4
282 3430 Jeyalakshmi 65 F 1 34.24 1 1 1 1 160 28 15 3.5 2 H 2 10.7
283 83045 Parvathy 67 F 0 24.03 1 1 0 1 200 41 30 3.3 0.768 H 2 ND
284 27337 Kasimeena 52 F 0 28.13 1 1 1 1 200 41 28 3.2 0.761 H 2 6.8
285 6192 Neelamegam 44 M 0 22.05 1 0 0 0 200 48 22 3.6 N/A N/A 0 N/A
286 89551 Musthaan 65 F 0 28.3 1 1 1 1 260 51 30 3 0.843 H 3 8.4
287 80805 Banumathi 48 F 0 22.67 0 0 0 0 300 28 18 3.2 N/A N/A 0 N/A
288 3075 Samsubeevi 58 F 0 24.97 1 0 0 0 300 40 21 3.3 N/A N/A 0 N/A
289 63720 Prema 48 F 0 24.24 1 1 0 1 160 30 15 3.9 0.836 H 2 ND
290 70192 Gurudevi 46 F 0 27.39 1 1 0 1 180 41 28 3.1 0.795 H 2 ND
291 83380 Gnanammal 65 F 0 24.89 1 1 0 1 320 32 26 3.2 -0.854 I 3 7.8
292 87225 Rani 54 F 0 28.13 1 1 1 1 260 32 15 3.4 N/A N/A 0 N/A
293 87968 Srinivasan 67 M 0 25.61 1 0 0 0 180 31 22 3.8 N/A N/A 0 N/A
294 1567 Kantha 56 F 1 31.96 1 1 1 1 180 33 16 3.4 1.989 H 3 8.4
295 48375 Eswaran 59 M 1 30.06 1 1 1 1 200 42 20 3.2 1.831 H 3 9.1
296 6705 Bujjammaal 65 F 0 20 0 0 0 0 180 36 21 3.1 N/A N/A 0 N/A
S.NO H.NO NAME AGE SEX BP BMI WC HTG HDL MS PLT AST ALT Alb NFS RF USG FLS
297 3260 Amsa 60 F 1 30.13 1 0 0 0 180 41 28 3 N/A N/A 0 N/A
298 6788 Ramamoorthy 39 M 1 32.08 1 1 0 1 200 41 30 3.2 0.555 I 1 N/A
299 98366 Sampathkumar 59 M 0 28.72 1 1 1 1 200 38 21 3.2 1.417 H 3 6.7
300 6784 Lakshmi 50 F 0 28.06 1 1 1 1 160 48 31 3.2 1.284 H 1 N/A
301 3679 Kanaga 51 F 0 22.67 1 1 0 1 300 32 20 3 -0.823 I 2 ND
302 53776 Sundari 63 F 1 32.73 1 1 1 1 200 41 22 3.6 2 H 3 12.3
303 74918 Subhulakshmi 52 F 0 23.81 1 0 0 0 220 32 15 3.7 N/A N/A 0 N/A
304 37854 Meharunisha 62 F 0 25.15 1 0 0 0 200 21 19 3.5 N/A N/A 0 N/A
305 13686 Thangam 66 F 0 27.47 1 0 1 1 200 28 24 4.5 0.064 I 1 N/A
306 20123 Johnbeevi 50 F 0 25.81 1 0 0 0 210 45 28 4.5 N/A N/A 0 N/A
307 6143 Marimuthu 39 M 0 25.04 0 0 0 0 250 54 32 3.8 N/A N/A 0 N/A
308 95361 Anjalai 62 F 1 31.18 1 1 1 1 260 20 15 5 -0.68 I 2 ND
309 5723 Omana 62 F 1 33.3 1 1 1 1 280 28 15 3.6 0.711 H 2 7.7
310 4577 Selvam 51 M 0 22.86 0 0 0 0 240 19 14 4.4 N/A N/A 0 N/A
311 6430 Arokiyam 64 M 0 27.68 1 1 1 1 180 42 38 3.6 0.803 H 2 ND
312 7082 Somasundaram 41 M 0 22.86 0 0 0 0 250 20 16 3.9 N/A N/A 0 N/A
313 40939 Kasturi 62 F 0 26.16 1 0 0 0 210 38 25 4.6 -0.053 I 1 N/A
314 26328 Elizabeth 45 F 1 32 1 1 1 1 160 39 55 3.1 0.704 H 3 7.6
315 7916 Karunakaran 44 M 0 22.31 1 0 0 0 190 51 41 5 N/A N/A 0 N/A
316 29301 Chellama 75 F 0 24.44 1 1 0 1 250 30 24 3.9 -0.059 I 2 ND
317 55101 Vasantha 40 F 0 23.95 1 0 0 0 280 19 16 3 N/A N/A 0 N/A
318 9 Balasundaram 71 M 0 21.64 0 0 0 0 210 21 17 3.4 0.365 I 1 N/A
319 7642 Lakshminarayananan 38 F 0 23.51 1 0 0 0 200 16 12 3.4 N/A N/A 0 N/A
320 3401 Kanchana 58 F 0 26.84 1 1 0 1 210 31 24 4.4 -0.231 I 2 ND
321 3092 Chandra 58 F 0 20.17 0 0 0 0 280 24 21 3.9 N/A N/A 0 N/A
322 1869 Saraswathi 42 F 0 27.06 1 1 1 1 210 45 39 4.8 N/A N/A 0 N/A
323 64008 Quraishabeevi 66 F 1 32.76 1 1 1 1 210 19 16 4 0.782 H 2 9.1
324 12 Dilshad 45 F 1 30.08 1 1 1 1 210 59 41 4.2 -0.13 I 2 8.8
325 103080 Vijaya 51 F 0 28.76 1 1 1 1 220 16 13 2.9 0.49 I 2 ND
326 103060 Lakshmi 50 F 0 22.96 1 0 0 0 180 26 22 3.7 N/A N/A 0 N/A
327 1533 Shanmugakani 50 F 0 29.14 1 1 1 1 195 39 26 3.4 0.75 H 2 7.6
328 615 Parvathy 60 F 0 20.82 1 0 0 0 200 41 38 4.6 N/A N/A 0 N/A
329 42406 Kathijabai 65 F 0 24.14 0 0 0 0 230 21 17 3.4 N/A N/A 0 N/A
330 41613 Gunasekaran 59 M 0 22.76 0 0 0 0 180 24 21 4.5 N/A N/A 0 N/A
331 83298 Vincent paul 63 M 0 20.96 0 0 0 0 200 38 24 3.5 0.414 I 1 N/A
332 85381 Maragadham 54 F 1 31.14 1 1 1 1 210 18 16 3.9 0.32 I 1 N/A
333 85382 Mariyamma 74 F 0 27.28 1 1 1 1 250 45 31 4.9 N/A N/A 0 N/A
334 81670 Thenmozhi 41 F 1 36.44 1 1 1 1 260 54 42 3.5 -0.02 I 3 5.4
335 67815 Kaliappan 70 M 0 26.78 1 1 0 1 210 81 55 3 1.31 H 2 ND
336 71679 Govindammal 60 F 0 22.06 1 0 0 0 180 39 24 4.2 N/A N/A 0 N/A
337 71722 Shanthi 63 F 0 23.74 0 0 0 0 190 29 24 3.4 N/A N/A 0 N/A
338 92450 Uma 50 F 0 20.93 0 0 0 0 190 39 25 3.7 N/A N/A 0 N/A
339 49642 Chaellammal 57 F 0 22.22 1 0 0 0 260 26 22 3.9 N/A N/A 0 N/A
340 5918 Vannamma 51 F 1 30.3 1 1 1 1 180 21 19 3.1 0.898 H 2 ND
341 37 Govindasamy 70 M 0 18.42 0 0 0 0 180 40 26 4.2 N/A N/A 0 N/A
342 1729 Vigneshwari 46 F 0 23.14 1 0 0 0 200 39 22 4.2 -0.285 I 1 N/A
343 2037 Kumar 47 M 0 25.71 1 0 0 0 200 26 21 3.1 N/A N/A 0 N/A
344 93446 Lakshmi 72 F 0 25.11 1 0 0 0 180 29 21 3.9 N/A N/A 0 N/A
345 51570 Kasturi 63 F 0 24.2 1 0 0 0 210 42 29 5.6 N/A N/A 0 N/A
346 93022 Valarmathi 48 F 0 21.08 1 0 0 0 160 29 22 4.1 N/A N/A 0 N/A
347 6778 Padmini 55 F 0 23.46 1 1 0 1 160 25 18 3.2 0.878 H 2 ND
348 1426 Valliamma 70 F 1 31.22 1 1 1 1 200 29 26 4.1 0.778 H 2 ND
349 81746 Mariambeevi 55 F 1 36.73 1 1 1 1 180 34 26 3.5 1.587 H 2 13.1
350 80134 Rasoolbeevi 43 F 0 29.14 1 1 1 1 210 21 19 2.9 0.235 I 1 N/A
351 3265 Neela 48 F 0 23.78 1 0 0 0 180 21 18 3.4 N/A N/A 0 N/A
352 104418 Vasuki 45 F 0 22.64 1 0 0 0 200 39 22 3.1 N/A N/A 0 N/A
353 85894 Subramani 73 M 0 21.91 0 0 0 0 210 21 15 3.4 0.628 H 2 7.4
354 63438 Shanmugam 56 M 0 23.03 1 1 1 1 190 49 20 4.5 0.677 H 3 7.7
355 95998 Arumugasamy 67 M 0 28.35 1 1 1 1 210 18 17 2.9 1.003 H 3 8.1
356 66282 Zerin bose 38 F 0 22.38 1 0 0 0 210 25 18 3.7 N/A N/A 0 N/A
357 90624 Eswari 46 F 0 22.01 0 0 0 0 250 32 19 3.9 N/A N/A 0 N/A
358 6721 Sivagami 35 F 1 31.96 1 1 1 1 190 49 22 4.9 0.255 I 2 ND
359 5417 Hyathnisha 41 F 1 34.63 1 1 1 1 160 19 16 5 0.023 I 2 5.3
360 88859 Lakshmi 60 F 0 24.45 1 0 0 0 200 23 21 3.2 N/A N/A 0 N/A
361 26122 Malliga 48 F 0 20.03 1 0 0 0 200 19 14 4.6 N/A N/A 0 N/A
362 4303 Ismail 59 M 0 22.31 0 0 0 0 210 33 29 4.6 -0.904 I 1 N/A
363 6116 Padmavathy 60 F 0 25.11 1 0 0 0 250 43 22 3.1 N/A N/A 0 N/A
364 77742 Amirthavalli 60 F 0 22.49 1 0 0 0 180 58 39 3.4 0.677 H 1 N/A
365 82937 Santhanalakshmi 60 F 0 28.89 1 1 1 1 250 26 21 2.8 0.518 I 1 N/A
366 95417 Puspa 58 F 0 25.21 1 0 0 0 210 54 39 4.7 N/A N/A 0 N/A
367 87799 Rameezabeevi 62 F 0 29 1 1 1 1 200 30 21 3 1.309 H 2 ND
368 97429 Karpagam 45 F 0 29.59 1 1 1 1 220 27 21 3.1 0.268 I 1 N/A
369 23198 Thamayandhi 46 F 0 24.65 1 1 0 1 210 36 28 4.5 -0.953 I 2 ND
370 91175 Annamalai 75 M 0 21.87 1 0 0 0 210 49 40 4.9 N/A N/A 0 N/A
S.NO H.NO NAME AGE SEX BP BMI WC HTG HDL MS PLT AST ALT Alb NFS RF USG FLS
371 102273 Subramani 71 M 0 26.71 1 1 1 1 210 21 18 3.7 0.576 I 3 6.8
372 6008 Puspa 36 F 0 27.77 1 1 1 1 200 21 19 3.8 N/A N/A 0 N/A
373 96908 Pargunan 37 M 0 27.99 1 1 1 1 180 55 32 3.8 N/A N/A 0 N/A
374 88590 Sekar 49 M 0 18.34 0 0 0 0 210 55 29 3.8 N/A N/A 0 N/A
375 70571 Yasodha 61 F 0 29.34 1 1 1 1 190 29 25 2.7 1.366 H 2 ND
376 82968 Selvi 52 F 0 24.03 1 0 0 0 170 51 38 4 0.117 I 1 N/A
377 55646 Kantha 60 F 1 32 1 1 1 1 250 44 28 3.6 0.613 I 1 N/A
378 32765 Farida 43 F 0 24.84 1 1 0 1 160 19 16 4.6 -0.559 I 2 5.3
379 70066 Sabiya 47 F 0 24.98 1 0 0 0 240 32 28 3.7 N/A N/A 0 N/A
380 2149 Aseenabegum 40 F 1 30.13 1 1 1 1 200 25 16 4.1 0.008 I 2 ND
381 100276 Andal 55 F 0 23.14 1 0 0 0 140 33 21 3.8 N/A N/A 0 N/A
382 102371 Sarada 42 F 1 30.48 1 1 1 1 160 40 25 4 0.738 H 2 10.4
383 55613 Sathaar 59 M 0 24.69 1 1 1 1 300 18 15 3.6 -1.129 I 3 5.3
384 79429 Gowsiya 52 F 0 27.83 1 1 0 1 150 27 18 3.9 0.956 H 2 7.7
385 4620 Saraswathi 52 F 1 30.92 1 1 1 1 200 25 16 3.9 0.658 I 2 ND
386 7420 Gajalakshmi 50 F 0 23.81 1 0 0 0 240 26 19 3.2 -0.334 I 1 N/A
387 66435 Prema 55 F 1 30.96 1 1 1 1 300 16 12 4.1 -0.886 I 1 N/A
388 91998 Leelavathy 66 F 1 30.08 1 1 1 1 180 28 16 3.5 1.807 H 1 N/A
389 88596 Raziyabegum 50 F 1 30.13 1 0 0 0 260 25 13 4.4 N/A N/A 0 N/A
390 89107 Jaibunisha 60 F 0 29.08 1 1 1 1 140 38 17 3.6 2 H 2 ND
391 102137 Paramasivam 65 M 0 23.38 1 1 0 1 300 19 12 3.3 -0.453 I 2 6.5
392 68167 Lakshmi 58 F 1 31.96 1 1 1 1 260 15 19 3.6 -0.369 I 1 N/A
393 3410 Latha 40 F 0 23.73 1 0 0 0 360 37 19 3.5 N/A N/A 0 N/A
394 7091 Vasanthi 53 F 0 25.63 1 0 0 0 240 41 31 3.8 -0.493 I 1 N/A
395 972 Govindammal 38 F 0 27.06 1 0 1 1 380 21 16 4.6 -2.5 L 1 N/A
396 98735 Manoranjidham 35 F 0 26.16 1 1 0 1 260 37 15 5.2 -1.161 I 2 ND
397 90135 Rose 47 F 0 23.44 1 0 0 0 160 22 13 4.5 N/A N/A 0 N/A
398 6131 Senbagavalli 44 F 1 30.86 1 1 1 1 180 19 14 3.8 0.479 I 2 7.7
399 83255 Gowri 52 F 1 31.5 1 1 1 1 200 25 16 4.8 0.119 I 1 N/A
400 66366 Selvammal 64 F 0 23.5 1 0 0 0 300 25 17 3.9 -0.986 I 1 N/A
401 2931 Suchitra 35 F 0 25.15 1 0 0 0 180 42 31 4.2 -0.657 I 1 N/A
402 55 Vanitha 45 F 0 21 1 0 0 0 240 28 17 3.8 -0.903 I 1 N/A
403 63640 Rukmani 66 F 0 26.52 1 1 0 1 240 25 17 4.2 -0.046 I 2 ND
404 3095 Gnanasoundari 49 F 0 29.55 1 1 1 1 240 22 16 4.1 -0.419 I 2 ND
405 1265 Kannatha 50 F 0 24.26 1 0 0 0 300 25 18 3.7 -1.382 I 1 N/A
406 76846 Yasodha 60 F 0 24.89 1 1 0 1 260 18 13 3.8 -0.503 I 2 ND
407 2570 Kulandaiyamma 58 F 0 25.39 1 0 0 0 240 39 16 3.5 0.971 H 1 N/A
408 77431 Bowsiya 58 F 1 31.96 1 1 1 1 260 20 14 4.2 -0.132 I 2 6.5
409 210013 Anandhi 52 F 1 30.76 1 0 0 0 340 25 18 3.5 N/A N/A 0 N/A
410 82400 Ponnamma 65 F 0 27.28 1 1 0 1 260 21 16 3.9 -0.23 I 2 ND
411 83018 Panneer 68 M 1 30.48 1 1 1 1 250 24 19 3.2 0.725 H 2 ND
412 3800 Murugavel 63 M 0 23.83 0 0 0 0 160 26 21 3.2 N/A N/A 0 N/A
413 104453 Mariyappan 47 M 0 20.55 0 0 0 0 140 18 15 4.4 N/A N/A 0 N/A
414 26708 Vasantha 67 F 0 24.44 1 1 0 1 110 22 19 3.6 1.572 H 2 9.1
415 92102 Rajasekar 51 M 1 31.02 1 1 1 1 160 19 14 4.4 0.617 I 2 ND
416 105191 Dhanalakshmi 37 F 0 22.51 1 0 0 0 180 32 29 3.1 N/A N/A 0 N/A
417 48412 Seetha 60 F 0 27.77 1 1 0 1 140 46 34 3 1.825 H 2 ND
418 2177 Rameeza 43 F 0 26.52 1 0 0 0 200 39 28 3.1 0.272 I 1 N/A
419 194083 Hazira 73 F 0 25.43 1 0 0 0 180 58 31 4.4 1.155 H 1 N/A
420 51832 Majidha 65 F 0 24.44 1 0 0 0 100 29 20 2.9 N/A N/A 0 N/A
421 101266 Krishnaveni 61 F 0 26.63 1 0 0 0 180 56 32 3.1 1.562 H 1 N/A
422 70368 Glory 38 F 1 37.18 1 1 1 1 300 40 19 3 0.56 I 2 7.7
423 67586 Isravel 66 M 0 22.58 1 0 0 0 280 49 26 3.6 -0.131 I 1 N/A
424 40492 Valliammal 40 F 0 22.31 1 0 0 0 200 19 17 3.4 N/A N/A 0 N/A
425 64775 Rajathi 60 F 0 27.56 1 1 0 1 200 65 38 3.6 0.983 H 2 ND
426 8721 Kanthamma 70 F 0 26.16 1 1 0 1 160 19 15 3 1.698 H 2 ND
427 56 Balu 62 M 0 23.05 1 1 0 1 140 21 16 4 0.755 H 2 6.8
428 21980 Madhinabegum 65 F 1 31.22 1 1 1 1 100 29 24 3.4 2 H 2 ND
429 85078 Anjalakshmi 61 F 0 22.35 0 0 0 0 100 29 26 3.5 1.307 H 2 ND
430 39087 Angamma 60 F 0 24.24 1 1 0 1 160 42 39 4.5 -0.03 I 2 ND
431 101719 Shanthi 50 F 1 33.33 1 0 1 1 200 29 26 3.6 N/A N/A 0 N/A
432 51653 Vasanthi 50 F 1 31.11 1 1 1 1 200 31 24 3.5 0.598 I 2 ND
433 63329 Parimala 60 F 0 28.95 1 1 1 1 180 21 15 3 N/A N/A 0 N/A
434 98390 Rani 63 F 0 21.63 1 0 0 0 200 59 32 3.2 N/A N/A 0 N/A
435 24712 Shanthi 52 F 0 29.59 1 1 1 1 200 19 46 5.6 N/A N/A 0 N/A
436 92828 Vasantha 66 F 0 29.94 1 1 1 1 100 25 21 5.4 1.026 H 2 6.3
437 5642 Varalakshmi 49 F 0 26.22 1 0 0 0 200 19 16 3.1 0.262 I 1 N/A
438 4371 Banu 42 F 0 25.8 1 1 0 1 200 35 21 4.6 -0.552 I 2 4.2
439 74991 Chengan 51 M 1 30.07 1 1 0 1 300 19 16 2.9 -0.47 I 1 N/A
440 2543 Govindammal 50 F 0 23.07 1 0 0 0 100 28 24 4.6 N/A N/A 0 N/A
441 41028 Annamma 66 F 0 22.32 1 0 0 0 140 24 18 4.2 0.723 H 1 N/A
442 5381 Nithyakalyani 55 F 0 23.93 1 0 0 0 160 22 15 4 N/A N/A 0 N/A
443 4101 Pramila 60 F 0 25.57 1 0 0 0 180 27 18 3.9 0.65 I 1 N/A
S.NO H.NO NAME AGE SEX BP BMI WC HTG HDL MS PLT AST ALT Alb NFS RF USG FLS
444 104747 Anjalai 36 F 0 24.77 1 0 0 0 300 38 21 3.9 N/A N/A 0 N/A
445 3856 Valli 58 F 0 28.57 1 1 1 1 140 30 21 3.6 1.505 H 2 ND
446 1150 Valliarasu 53 F 0 22.84 1 0 0 0 180 32 15 4 0.695 H 1 N/A
447 105286 Indrani 43 F 0 20 0 0 0 0 200 36 15 3.6 N/A N/A 0 N/A
448 106333 Ganesan 54 M 0 24.22 1 0 0 0 240 38 15 3.1 N/A N/A 0 N/A
449 47 Malarkodi 57 F 1 35.71 1 1 1 1 140 25 14 3.5 2 H 2 ND
450 63609 Rani 55 F 0 24.03 1 1 0 1 280 28 15 3.6 -0.419 I 2 ND
451 91947 Kalyani 55 F 0 23.44 1 1 0 1 120 30 18 4.1 1.077 H 2 5.4
452 5570 Rani 47 F 0 21.08 1 0 0 0 200 32 28 4.2 N/A N/A 0 N/A
453 89099 Fathimabeevi 67 F 0 29.67 1 1 1 1 260 32 15 3.9 0.881 H 2 ND
454 86011 Rani 63 F 0 24.73 1 1 0 1 180 36 21 3.8 0.96 H 2 ND
455 1209 Kanthammal 65 F 0 22.22 1 1 0 1 160 31 22 3.6 0.888 H 2 5.3
456 1347 Aruna 53 F 0 20.31 1 0 0 0 140 38 19 3.5 N/A N/A 0 N/A
457 466 Ranjan 57 M 0 26.3 1 0 0 0 300 25 18 4 -1.129 I 1 N/A
458 5780 Sivagami 70 F 0 24.94 1 1 0 1 180 25 18 3.7 0.982 H 2 ND
459 2646 Poonkodi 52 F 0 28.47 0 0 1 0 290 28 15 3.3 0.085 I 1 N/A
460 2915 Parameshwari 52 F 0 25.57 1 1 0 1 140 28 15 3.1 1.765 H 2 ND
461 105143 Sarfunisha 50 F 0 26.16 1 0 0 0 100 38 29 3.7 1.319 H 1 N/A
462 98827 Subedha 55 F 0 27.06 1 0 1 1 160 28 15 3.1 1.756 H 1 N/A
463 6290 Joseph 64 M 0 25.78 1 1 0 1 180 36 18 4.3 1.048 H 2 ND
464 92851 Devika 44 F 1 38.02 1 1 1 1 340 42 31 3.8 -0.93 I 1 N/A
465 1812 Anushya 52 F 1 33.28 1 1 1 1 300 28 15 3.1 0.409 I 2 ND
466 89281 Noorjahan 52 F 0 25.11 1 0 0 0 160 31 22 3.4 N/A N/A 0 N/A
467 2093 Lally 46 F 1 31.63 1 1 1 1 180 28 31 4 0.044 I 2 ND
468 98123 Chandran 63 M 0 18 0 0 0 0 100 28 15 3.2 N/A N/A 0 N/A
469 74693 Backiyam 62 F 0 25.33 1 1 0 1 180 31 22 3 1.205 H 2 7.8
470 74054 Parvathy 39 F 0 24.34 1 0 0 0 140 25 18 3.9 0.167 I 1 N/A
471 70610 Samsudin 48 M 1 33.95 1 1 1 1 300 33 28 3.6 -0.687 I 2 ND
472 232 Rashidhabegum 60 F 1 30.13 1 1 1 1 200 28 26 4 0.333 I 2 ND
473 95013 Anjalai 45 F 0 29.21 1 1 1 1 280 34 32 3.8 -1.23 I 1 N/A
474 88274 Helen 66 F 0 24.56 1 1 0 1 160 26 32 4.2 0.524 I 2 7.6
475 67036 Revathy 47 F 0 28.57 1 1 1 1 180 40 36 3.8 0.132 I 1 N/A
476 2176 Kalaiarasi 37 F 1 31.53 1 1 1 1 100 42 40 4 0.887 H 1 N/A
477 63605 Chandra 59 F 0 26.67 1 1 0 1 300 38 33 3.9 -1.189 I 2 ND
478 181 Susairani 43 F 0 23.19 1 0 0 0 200 26 28 3.6 N/A N/A 0 N/A
479 91413 Valliammal 55 F 0 26.4 1 0 0 0 160 29 27 3.9 N/A N/A 0 N/A
480 79803 Chinnaponnu 60 F 0 24.44 1 0 0 0 180 20 18 4.2 N/A N/A 0 N/A
481 5382 Meharbaanbeevi 65 F 0 20.54 1 0 0 0 280 30 31 3 -0.871 I 1 N/A
482 5088 Lakshmi 65 F 0 27.59 1 1 0 1 170 29 28 3.1 1.223 H 2 ND
483 80045 Fathima 58 F 0 22.48 1 1 0 1 320 26 20 3.8 -1.667 L 2 N/A
484 4981 Vellammal 40 F 0 21.93 1 0 0 0 280 38 31 3.7 N/A N/A 0 N/A
485 32190 Lakshmi 66 F 0 25.45 1 1 0 1 180 29 20 3 1.405 H 2 ND
486 33450 Sarada 50 F 0 26.22 1 1 0 1 160 30 29 3.6 0.338 I 2 10.4
487 1298 Selvi 60 F 1 31.08 1 1 1 1 140 29 20 3.8 1.704 H 3 6.8
488 3456 Vasantha 49 F 1 42.42 1 1 1 1 160 32 30 3.5 1.921 H 3 9.1
489 1245 Sakeela 45 F 1 32.44 1 1 1 1 200 42 31 3.1 0.865 H 1 N/A
490 1815 Anandh 57 M 0 22.31 0 0 0 0 240 31 32 3.1 N/A N/A 0 N/A
491 1488 Kanagavalli 58 F 0 24.56 1 0 0 0 160 24 22 3.4 N/A N/A 0 N/A
492 67081 Nageshwari 50 F 0 16 0 0 0 0 400 25 20 3.2 N/A N/A 0 N/A
493 99701 Vasantha 55 F 0 27.43 1 1 0 1 180 18 15 3.1 0.87 H 2 6.3
494 6647 Malliga 63 F 0 23.61 1 1 0 1 260 28 20 3 0.031 I 2 7.8
495 103530 Azad 55 M 0 27.43 1 1 1 1 400 29 32 3.9 N/A N/A 0 N/A
496 1706 Md.Hussain 56 M 0 25.22 1 0 0 0 350 20 16 3.6 N/A N/A 0 N/A
497 48656 Rajeshwari 57 F 0 28.36 1 1 1 1 160 21 18 3.2 1.193 H 1 N/A
498 69425 Layala 50 F 0 29.55 1 1 1 1 200 18 16 3.7 0.154 I 1 N/A
499 50182 Ameenabeevi 60 F 1 33.2 1 1 1 1 240 22 20 3.2 0.653 I 2 10.3
500 375 Violet maria 60 F 0 25.11 1 1 0 1 150 26 28 3.8 0.497 I 2 6.3
KEY:
S.NO:serial number, H.NO:hospital number, M=Male ,F=Female,   BP (BLOOD
PRESURE>135/85mmhg), N/A=NOT APPLICABLE, PRESENT=1, ABSENT=0, BMI=Body Mass
Index in kg/m2, WC=WAIST CIRCUMFERENCE M>90CM, F>80CM for central obesity,
HTG=HYPERTRIGLYCERIDEMIA ,HDL= High density lipoprotien LOW= M<40, F<50,
MS=Metabolic syndrome, PLT=Platelet count in(10^9/L) AST=Aspartate aminotransferase,
ALT=Alanine aminotransferase ,Alb=Albumin, NFS=NAFLD Fibrosis score, RF=RISK OF
FIBROSIS(L=LOW,I=INDETERMINATE,H=HIGH), USG =Ultrasound ABDOMEN -FATTY LIVER
GRADE(0=NO ,1=GRADE 1,2=GRADE 2,3=GRADE 3), FLS=FIBROSCAN FINDINGS(liver stiffness
in kPa), ND=NOT DONE.
